<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" id="cbdd70130" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Chem Biol Drug Des</journal-id><journal-id journal-id-type="iso-abbrev">Chem Biol Drug Des</journal-id><journal-id journal-id-type="doi">10.1111/(ISSN)1747-0285</journal-id><journal-id journal-id-type="publisher-id">CBDD</journal-id><journal-title-group><journal-title>Chemical Biology &#x00026; Drug Design</journal-title></journal-title-group><issn pub-type="ppub">1747-0277</issn><issn pub-type="epub">1747-0285</issn><publisher><publisher-name>John Wiley and Sons Inc.</publisher-name><publisher-loc>Hoboken</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40405627</article-id><article-id pub-id-type="pmc">PMC12099485</article-id>
<article-id pub-id-type="doi">10.1111/cbdd.70130</article-id><article-id pub-id-type="publisher-id">CBDD70130</article-id><article-id pub-id-type="other">CBDD-RA-01-25-8569</article-id><article-categories><subj-group subj-group-type="overline"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Structural Insights Into Papain&#x02010;Derived Synthetic Antibacterial Peptides for Targeting <styled-content style="fixed-case" toggle="no">
<italic toggle="no">Klebsiella pneumoniae</italic>
</styled-content>
</article-title></title-group><contrib-group><contrib id="cbdd70130-cr-0001" contrib-type="author"><name><surname>Ferreira</surname><given-names>Marcos Ant&#x000f4;nio</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-0690-891X</contrib-id><xref rid="cbdd70130-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="cbdd70130-cr-0002" contrib-type="author"><name><surname>Silva</surname><given-names>Patr&#x000ed;cia Souza e</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-4968-2810</contrib-id><xref rid="cbdd70130-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="cbdd70130-cr-0003" contrib-type="author"><name><surname>Lacerda</surname><given-names>Adriel Parahyba</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-4987-7922</contrib-id><xref rid="cbdd70130-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="cbdd70130-cr-0004" contrib-type="author"><name><surname>Franco</surname><given-names>Pedro de Mattos</given-names></name><xref rid="cbdd70130-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="cbdd70130-cr-0005" contrib-type="author"><name><surname>da Silva</surname><given-names>Fhillipe Ferreira Deodato</given-names></name><xref rid="cbdd70130-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="cbdd70130-cr-0006" contrib-type="author"><name><surname>de Souza</surname><given-names>Thalis Ferreira</given-names></name><xref rid="cbdd70130-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="cbdd70130-cr-0007" contrib-type="author"><name><surname>Macedo</surname><given-names>Maria Ligia R.</given-names></name><xref rid="cbdd70130-aff-0003" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib id="cbdd70130-cr-0008" contrib-type="author" corresp="yes"><name><surname>Migliolo</surname><given-names>Ludovico</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-6606-2189</contrib-id><xref rid="cbdd70130-aff-0002" ref-type="aff">
<sup>2</sup>
</xref><address><email>ludovico@ucdb.br</email></address></contrib><contrib id="cbdd70130-cr-0009" contrib-type="author"><name><surname>de Oliveira</surname><given-names>Jefferson Soares</given-names></name><xref rid="cbdd70130-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib></contrib-group><aff id="cbdd70130-aff-0001">
<label>
<sup>1</sup>
</label>
<institution>Universidade Federal do Delta do Parna&#x000ed;ba &#x02013; UFDPar</institution>
<city>Parna&#x000ed;ba</city>
<country country="BR">Brazil</country>
</aff><aff id="cbdd70130-aff-0002">
<label>
<sup>2</sup>
</label>
<named-content content-type="organisation-division">S&#x02010;Inova Biotech, Programa de P&#x000f3;s&#x02010;Gradua&#x000e7;&#x000e3;o em Biotecnologia</named-content>
<institution>Universidade Cat&#x000f3;lica Dom Bosco</institution>
<city>Campo Grande</city>
<named-content content-type="country-part">MS</named-content>
<country country="BR">Brazil</country>
</aff><aff id="cbdd70130-aff-0003">
<label>
<sup>3</sup>
</label>
<named-content content-type="organisation-division">Laborat&#x000f3;rio de Purifica&#x000e7;&#x000e3;o de Prote&#x000ed;nas e suas Fun&#x000e7;&#x000f5;es Biol&#x000f3;gicas, Unidade de Tecnologia de Alimentos e da Sa&#x000fa;de P&#x000fa;blica</named-content>
<institution>Universidade Federal de Mato Grosso do Sul</institution>
<city>Campo Grande</city>
<named-content content-type="country-part">MS</named-content>
<country country="BR">Brazil</country>
</aff><author-notes><corresp id="correspondenceTo">
<label>*</label>
<bold>Correspondence:</bold>
<break/>
Ludovico Migliolo (<email>ludovico@ucdb.br</email>)<break/>
</corresp></author-notes><pub-date pub-type="epub"><day>23</day><month>5</month><year>2025</year></pub-date><pub-date pub-type="ppub"><month>5</month><year>2025</year></pub-date><volume>105</volume><issue seq="160">5</issue><issue-id pub-id-type="doi">10.1111/cbdd.v105.5</issue-id><elocation-id>e70130</elocation-id><history>
<date date-type="rev-recd"><day>04</day><month>5</month><year>2025</year></date>
<date date-type="received"><day>04</day><month>5</month><year>2025</year></date>
<date date-type="accepted"><day>11</day><month>5</month><year>2025</year></date>
</history><permissions><!--Copyright &#x000a9; 2025 John Wiley & Sons A/S--><copyright-statement content-type="article-copyright">&#x000a9; 2025 The Author(s). <italic toggle="yes">Chemical Biology &#x00026; Drug Design</italic> published by John Wiley &#x00026; Sons Ltd.</copyright-statement><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="file:CBDD-105-e70130.pdf"/><abstract><title>ABSTRACT</title><p>Bacterial resistance represents one of the greatest challenges in modern medicine, requiring innovative strategies. This study presents the rational design of two synthetic analogue peptides, WK&#x02010;MAP1, and WG&#x02010;MAP2, inspired by the structure of the enzyme papain (PDB 9PAP), emphasizing the novelty of using an enzyme as a model for developing new antimicrobials. Initially, in silico studies, including molecular modeling and docking experiments, revealed a high affinity of the peptides for mimetic bacterial membranes. Subsequently, in&#x000a0;vitro assays confirmed their antimicrobial efficacy. WK&#x02010;MAP1 demonstrated superior activity against carbapenem&#x02010;resistant <styled-content style="fixed-case" toggle="no">
<italic toggle="no">Klebsiella pneumoniae</italic>
</styled-content> (KPC+), with a minimum inhibitory concentration (MIC) of 25&#x02009;&#x003bc;M, whereas WG&#x02010;MAP2 exhibited activity against both tested strains (KPC+ and ATCC), with MICs of 50 and 100&#x02009;&#x003bc;M, respectively. Both peptides effectively inhibited biofilm formation and exhibited low cytotoxicity in murine cells. This research highlights the potential of WK&#x02010;MAP1 and WG&#x02010;MAP2 as promising candidates for novel antimicrobial therapies, offering an innovative approach to overcoming the limitations of conventional antibiotics.</p></abstract><abstract abstract-type="graphical"><p>The synthetic peptides WK&#x02010;MAP1 and WG&#x02010;MAP2, bioinspired by papain, demonstrated optimized activity, particularly against multidrug&#x02010;resistant <styled-content style="fixed-case" toggle="no">
<italic toggle="no">Klebsiella pneumoniae</italic>
</styled-content>, with improved sequence interaction profiles, membrane affinity, and predicted antimicrobial and antibiofilm efficacy, supporting their potential as therapeutic peptide candidates.<boxed-text position="anchor" content-type="graphic" id="cbdd70130-blkfxd-0001"><graphic xlink:href="CBDD-105-e70130-g001.jpg" position="anchor" id="jats-graphic-1"/></boxed-text>
</p></abstract><kwd-group kwd-group-type="author-generated"><kwd id="cbdd70130-kwd-0001">antimicrobial peptides</kwd><kwd id="cbdd70130-kwd-0002">bacterial resistance</kwd><kwd id="cbdd70130-kwd-0003">biofilms</kwd><kwd id="cbdd70130-kwd-0004">enzyme model</kwd><kwd id="cbdd70130-kwd-0005">molecular docking</kwd><kwd id="cbdd70130-kwd-0006">papain</kwd></kwd-group><counts><fig-count count="8"/><table-count count="2"/><page-count count="13"/><word-count count="8900"/></counts><custom-meta-group><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>May 2025</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:6.5.6 mode:remove_FC converted:23.05.2025</meta-value></custom-meta></custom-meta-group></article-meta><notes><fn-group id="cbdd70130-ntgp-0001"><fn fn-type="funding" id="cbdd70130-note-0001"><p>
<bold>Funding:</bold> The authors received no specific funding for this work.</p></fn><fn id="cbdd70130-note-0101"><p>The authors Marcos Ant&#x000f4;nio Ferreia and Adriel Parahyba Lacerda contributed equally to this work.</p></fn></fn-group></notes></front><body id="cbdd70130-body-0001"><sec id="cbdd70130-sec-0001"><label>1</label><title>Introduction</title><p>The increasing prevalence of antibiotic resistance and biofilm formation in microbial infections has become a significant global health concern, necessitating the search for novel antimicrobial and antibiofilm agents. In this regard, brown algae from the Red Sea, particularly <italic toggle="yes">Sargassum</italic> sp., have garnered attention as a rich source of bioactive compounds with potential therapeutic applications (Alreshidi et&#x000a0;al.&#x000a0;<xref rid="cbdd70130-bib-0002" ref-type="bibr">2023</xref>).</p><p>
<styled-content style="fixed-case" toggle="no">
<italic toggle="no">Klebsiella pneumoniae</italic>
</styled-content> is a clinically significant Gram&#x02010;negative opportunistic pathogen responsible for various infections, including urinary tract infections, bacteremia, pneumonia, and liver abscesses (Wang et&#x000a0;al.&#x000a0;<xref rid="cbdd70130-bib-0051" ref-type="bibr">2021</xref>). These infections can increase mortality rates in critically ill hospitalized patients and substantially raise hospital costs on a global scale (Ding et&#x000a0;al.&#x000a0;<xref rid="cbdd70130-bib-0009" ref-type="bibr">2023</xref>). Due to its high level of antibiotic resistance, <styled-content style="fixed-case" toggle="no">
<italic toggle="no">K. pneumoniae</italic>
</styled-content> was included in the World Health Organization's list of priority pathogens in February 2017, being recognized as one of the greatest threats to public health (De Oliveira et&#x000a0;al.&#x000a0;<xref rid="cbdd70130-bib-0008" ref-type="bibr">2020</xref>). The predominant resistance mechanism of this bacterium involves the inactivation of penicillins, as well as first&#x02010;, second&#x02010;, and third&#x02010;generation cephalosporins and aztreonam, through the hydrolysis of these antibiotics by the &#x003b2;&#x02010;lactamase enzyme (Hennequin and Robin&#x000a0;<xref rid="cbdd70130-bib-0020" ref-type="bibr">2016</xref>). Furthermore, <styled-content style="fixed-case" toggle="no">
<italic toggle="no">K. pneumoniae</italic>
</styled-content> exhibits a high capacity for biofilm formation, further complicating treatment.</p><p>Biofilm is a structured community of microorganisms embedded in an extracellular polymeric substance matrix (Versey et&#x000a0;al.&#x000a0;<xref rid="cbdd70130-bib-0050" ref-type="bibr">2021</xref>). Its formation occurs in four stages: (1) reversible bacterial attachment, (2) adhesion and proliferation, (3) maturation, and (4) biofilm dispersion. Studies indicate that 75% of clinical <styled-content style="fixed-case" toggle="no">
<italic toggle="no">Klebsiella pneumoniae</italic>
</styled-content> strains form biofilm. Additionally, 97.1% of multidrug&#x02010;resistant (MDR) isolates exhibit this capability, with those originating from blood, pus, and tracheal secretions being the most prone to biofilm formation (Versey et&#x000a0;al.&#x000a0;<xref rid="cbdd70130-bib-0050" ref-type="bibr">2021</xref>; Ashwath et&#x000a0;al.&#x000a0;<xref rid="cbdd70130-bib-0003" ref-type="bibr">2022</xref>). The ability to form biofilm is a critical virulence factor of <styled-content style="fixed-case" toggle="no">
<italic toggle="no">K. pneumoniae</italic>
</styled-content> (Li and Ni&#x000a0;<xref rid="cbdd70130-bib-0028" ref-type="bibr">2023</xref>). A newly emerging hypervirulent strain of <styled-content style="fixed-case" toggle="no">
<italic toggle="no">K. pneumoniae</italic>
</styled-content> (hvKp) has raised concerns within the World Health Organization due to its high infection rate and resistance to the latest classes of antibiotics (De Oliveira et&#x000a0;al.&#x000a0;<xref rid="cbdd70130-bib-0008" ref-type="bibr">2020</xref>).</p><p>Concurrently, the rising challenge of combating both antimicrobial resistance and cancer has driven the development of dual&#x02010;purpose drug candidates, highlighting the need for innovative strategies in drug discovery (Othman et&#x000a0;al.&#x000a0;<xref rid="cbdd70130-bib-0037" ref-type="bibr">2021</xref>). In this context, antimicrobial peptides (AMPs) have emerged as promising candidates due to their unique mechanisms of action, which significantly differ from those of traditional antibiotics. This distinct feature makes AMPs highly attractive alternatives for addressing resistant pathogens (Giuliani et&#x000a0;al.&#x000a0;<xref rid="cbdd70130-bib-0017" ref-type="bibr">2007</xref>). AMPs typically consist of 12&#x02013;50 amino acid residues, characterized by their positive charges and amphipathic structures (Klousnitzer et&#x000a0;al.&#x000a0;<xref rid="cbdd70130-bib-0026" ref-type="bibr">2024</xref>). They occur naturally in a wide range of organisms, including bacteria, plants, insects, and animals, and exhibit diverse therapeutic properties; plant&#x02010;derived AMPs have attracted considerable attention from the scientific and pharmaceutical communities due to their potential as models for the development of new antibiotic drugs (Gaur et&#x000a0;al.&#x000a0;<xref rid="cbdd70130-bib-0016" ref-type="bibr">2018</xref>; Slezina et&#x000a0;al.&#x000a0;<xref rid="cbdd70130-bib-0046" ref-type="bibr">2022</xref>). Furthermore, advances in chemical engineering have enabled the modification of AMPs to optimize key properties such as antimicrobial activity, target selectivity, solubility, and bioavailability (Riahifard et&#x000a0;al.&#x000a0;<xref rid="cbdd70130-bib-0041" ref-type="bibr">2018</xref>; Falcigno et&#x000a0;al.&#x000a0;<xref rid="cbdd70130-bib-0013" ref-type="bibr">2021</xref>). These modifications allow for the rational design of AMPs tailored to specific therapeutic needs.</p><p>Among natural bioactive compounds, papain, a cysteine protease derived from the latex of <styled-content style="fixed-case" toggle="no">
<italic toggle="no">Carica papaya</italic>
</styled-content>, has demonstrated notable antimicrobial properties (Juntavee et&#x000a0;al.&#x000a0;<xref rid="cbdd70130-bib-1008" ref-type="bibr">2014</xref>). Studies reveal its efficacy against pathogens, such as <styled-content style="fixed-case" toggle="no">
<italic toggle="no">Staphylococcus aureus</italic>
</styled-content>, <styled-content style="fixed-case" toggle="no">
<italic toggle="no">Escherichia coli</italic>
</styled-content>, and <styled-content style="fixed-case" toggle="no">
<italic toggle="no">Pseudomonas aeruginosa</italic>
</styled-content>, as well as its applications in food technology, including the production of antimicrobial food packaging to prevent contamination (Mota et&#x000a0;al.&#x000a0;<xref rid="cbdd70130-bib-0035" ref-type="bibr">2015</xref>). These attributes make papain a valuable molecule in the fight against microbial resistance.</p><p>However, the reliance on natural papain presents challenges, including seasonal variability in papaya availability and inconsistencies in purity and composition due to extraction processes. Synthetic peptides inspired by papain offer a promising solution to these limitations. Laboratory synthesis provides better control over production conditions, ensuring consistent quality, minimizing impurities, and enabling modifications to reduce allergenicity and side effects (Wu et&#x000a0;al.&#x000a0;<xref rid="cbdd70130-bib-0054" ref-type="bibr">1998</xref>; Yazawa and Numata&#x000a0;<xref rid="cbdd70130-bib-0057" ref-type="bibr">2016</xref>). This approach not only circumvents the unpredictability of natural sources but also allows for the rational design of peptide analogues with enhanced antimicrobial properties.</p><p>Given these considerations, this study sought to design antibacterial peptides inspired by papain through rational approaches, such as molecular modeling and docking simulations. These advanced computational tools enable the identification of synthetic peptide analogues with enhanced efficacy, improved safety profiles, and greater potential to combat bacterial resistance. Such efforts aim to contribute to the development of next&#x02010;generation antimicrobial agents, addressing a critical global health challenge.</p></sec><sec sec-type="methods" id="cbdd70130-sec-0002"><label>2</label><title>Methods</title><sec id="cbdd70130-sec-0003"><label>2.1</label><title>Rational Design of Peptide Analogues</title><p>The three&#x02010;dimensional structure of papain was used as a reference model to derive the peptide analogues in this study. Papain is a protease comprising a single polypeptide chain with 212 amino acids, organized into two distinct domains: the L domain, characterized by three &#x003b1;&#x02010;helices, and the R domain, which contains an antiparallel &#x003b2;&#x02010;sheet. The active site of papain resides in a cleft between these two domains, containing a cysteine residue essential for its catalytic activity (Kamphuis et&#x000a0;al.&#x000a0;<xref rid="cbdd70130-bib-0023" ref-type="bibr">1984</xref>). The selection of the 18&#x02010;amino acid &#x003b1;&#x02010;helix WG&#x02010;18 (<sup>26</sup>WAFSAVVTIEGIIKIRTG<sup>43</sup>) as the study target was motivated by two fundamental characteristics. Firstly, the presence of the amino acid tryptophan at position 26 (Trp<sup>26</sup>) in this region is particularly significant due to its essential role in antimicrobial activity. Tryptophan is widely recognized as a critical component in AMPs because of its unique chemical properties, including its hydrophobicity and its ability to insert into and disrupt bacterial membranes. This property allows tryptophan to facilitate the interaction of AMPs with bacterial cell membranes, enhancing their efficacy in membrane permeabilization and cell lysis (Chan et&#x000a0;al.&#x000a0;<xref rid="cbdd70130-bib-0007" ref-type="bibr">2006</xref>). Additionally, tryptophan's indole side chain provides a unique electrostatic interaction capability, which contributes to the peptide's selective activity against bacterial cells while minimizing toxicity to mammalian cells (Yang et&#x000a0;al.&#x000a0;<xref rid="cbdd70130-bib-0056" ref-type="bibr">2024</xref>). Moreover, studies have shown that the positioning of tryptophan within the peptide sequence can further optimize its antimicrobial activity; for instance, peptides with tryptophan located near the N&#x02010; or C&#x02010;terminal regions often demonstrate improved efficacy against resistant strains of fungi and bacteria (Kim et&#x000a0;al.&#x000a0;<xref rid="cbdd70130-bib-0025" ref-type="bibr">2024</xref>).</p><p>The maintenance of the Trp<sup>26</sup> residue in WG18 was aiming at the central dogma of biology. Therefore, the proposal was to alter the physicochemical characteristics to develop new peptides, termed multi&#x02010;activity peptides (MAPs), specifically WK&#x02010;MAP1 and WG&#x02010;MAP2. The modified peptide WK&#x02010;MAP1 underwent structural reorganization with point mutations at positions Phe<sup>3</sup>, Val<sup>7</sup>, Tyr<sup>8</sup>, Arg<sup>16</sup>, and Gly<sup>18</sup>, substituted by Lys<sup>3</sup>, Lys<sup>7</sup>, Ala<sup>8</sup>, Leu<sup>16</sup>, and Lys<sup>18</sup>, respectively, resulting in a sequence where the positive charge is solely contributed by lysine residues. Similarly, the WG&#x02010;MAP2 analogue was reorganized with substitutions at Phe<sup>3</sup>, Val<sup>7</sup>, Tyr<sup>8</sup>, Glu<sup>10</sup>, and Arg<sup>16</sup>, replaced by Lys<sup>3</sup>, Lys<sup>7</sup>, Ala<sup>8</sup>, Arg<sup>10</sup>, and Ile<sup>16</sup>, respectively, effectively repositioning arginine and glutamic acid within the sequence. The three&#x02010;dimensional structure of papain was retrieved from the Protein Data Bank (PDB) with the accession code 9PAP (Drenth et&#x000a0;al.&#x000a0;<xref rid="cbdd70130-bib-0010" ref-type="bibr">1968</xref>). The structure model was predicted using the AlphaFold2 server and subsequently visualized with PyMOL 3.1 for analysis. The peptide sequences were analysed using the Schiffer&#x02010;Edmundson helical wheel projection via the HeliQuest server. Sequence alignments were performed using the Clustal Omega server version 1.2.4 to compare and calculate the percentages of identity and similarity between the native and modified sequences.</p></sec><sec id="cbdd70130-sec-0004"><label>2.2</label><title>Validation of Peptides</title><p>To validate the generated models, two distinct steps were undertaken. Firstly, MolProbity was employed to assess the geometry of the peptide molecules, stereochemistry, and energy distribution, also calculating the mean score for dihedral angles while considering the covalent forces involved. In addition, QMEAN&#x02010;Swiss Model was utilized to compute the overall quality <italic toggle="yes">Z</italic>&#x02010;score of the models, ensuring that the scores fell within the acceptable ranges for native proteins. Tools such as CAMPr4 (support vector machine [SVM], random forest [RF] and artificial neural network), Sense the Moment (Machine Learning Algorithm), HemoPI 2.0 (SVM), and ToxinPred (SVM) were used to predict antimicrobial and hemolytic activities. These tools use hybrid models and machine learning algorithms to provide robust classification based on known database patterns.</p></sec><sec id="cbdd70130-sec-0005"><label>2.3</label><title>Peptides Synthesis</title><p>The peptides were synthesized using the solid&#x02010;phase method with N&#x02010;9&#x02010;fluorenylmethoxycarbonyl (Fmoc) protection and subsequently purified by reverse&#x02010;phase high performance liquid chromatography (RP&#x02010;HPLC) to &#x0003e;&#x02009;95% purity in a gradient of acetonitrile: H<sub>2</sub>O:TFA. The molecular mass of the peptides was determined using electrospray mass spectrometry conducted by Aminotech Company (S&#x000e3;o Paulo, Brazil).</p></sec><sec id="cbdd70130-sec-0006"><label>2.4</label><title>Minimum Inhibitory Concentration (<styled-content style="fixed-case" toggle="no">MIC</styled-content>) and Minimum Bactericidal Concentration (<styled-content style="fixed-case" toggle="no">MBC</styled-content>)</title><p>The MIC assays were performed against <styled-content style="fixed-case" toggle="no">
<italic toggle="no">Klebsiella pneumoniae</italic>
</styled-content> (ATCC 13883) and <styled-content style="fixed-case" toggle="no">
<italic toggle="no">Klebsiella pneumoniae</italic>
</styled-content> (KPC&#x02009;+&#x02009;001450421) strains. The bacteria were plated on Mueller&#x02010;Hinton agar (MHA) plates and incubated overnight at 37&#x000b0;C. After this period, three colonies of each bacterium were inoculated into 5&#x02009;mL of Mueller&#x02010;Hinton broth (MHB) and incubated at 200&#x02009;rpm, at 37&#x000b0;C, overnight. Bacterial growth was monitored at 600&#x02009;nm using a spectrophotometer. The MIC assays were conducted using the microdilution method in 96&#x02010;well plates at a final bacterial concentration of 5&#x02009;&#x000d7;&#x02009;10<sup>6</sup>&#x02009;CFU&#x02009;mL<sup>&#x02212;1</sup>, as previously described (Wiegand et&#x000a0;al.&#x000a0;<xref rid="cbdd70130-bib-0053" ref-type="bibr">2008</xref>). The peptides were tested at concentrations ranging from 6.25 to 100&#x02009;&#x003bc;M. The antibiotic meropenem was used as a positive control at the same concentrations, whereas the bacterial suspension in MHB was used as a negative control. The microplates were incubated at 37&#x000b0;C for 18&#x02009;h. After incubation, the microplates were read on a Multiskan Go microplate reader (Thermo Scientific) at 600&#x02009;nm. MIC was determined as the lowest concentration of each fraction at which no significant bacterial growth was observed. For the MBC assays, 10&#x02009;&#x003bc;L from each well where the MIC was determined were plated on MHA plates and incubated at 37&#x000b0;C for 24&#x02009;h. MBC was defined as the lowest concentration of each fraction at which no bacterial growth was detected. Three independent experiments were performed for each condition tested.</p></sec><sec id="cbdd70130-sec-0007"><label>2.5</label><title>Minimum Biofilm Inhibitory Concentration (<styled-content style="fixed-case" toggle="no">MBIC</styled-content>)</title><p>Overnight cultures of <styled-content style="fixed-case" toggle="no">
<italic toggle="no">Klebsiella pneumoniae</italic>
</styled-content> (KPC&#x02009;+&#x02009;001450421) were diluted to 5&#x02009;&#x000d7;&#x02009;10<sup>6</sup>&#x02009;CFU.mL<sup>&#x02212;1</sup> in MHB medium and inoculated into Luria&#x02010;Bertani (LB) medium in 96&#x02010;well, round&#x02010;bottom cell culture microplates. The cultures were incubated in the presence of peptides at concentrations ranging from 6.25 to 100&#x02009;&#x003bc;M for 24&#x02009;h. The growth control contained only bacteria; Meropenem was used as a positive control for biofilm inhibition, whereas the negative growth controls contained only LB broth. After the incubation period, planktonic cells were removed, and the microplate wells were washed twice with deionized water. The remaining adherent bacteria were stained with 100&#x02009;&#x003bc;L of 0.1% crystal violet (w:v) for 20&#x02009;min. The microplates were washed twice with distilled water, air&#x02010;dried, and the biofilm was solubilized with 100&#x02009;&#x003bc;L of 60% ethanol. The content was transferred to a new microplate, and the MBIC of the peptides was measured at 595&#x02009;nm using a Multiskan Go microplate reader (Thermo Scientific). Three independent experiments were performed for each condition tested.</p></sec><sec id="cbdd70130-sec-0008"><label>2.6</label><title>Hemolytic Assay</title><p>Hemolytic assays were performed with fresh blood from <styled-content style="fixed-case" toggle="no">
<italic toggle="no">Mus musculus</italic>
</styled-content> mice, which were collected and centrifuged to separate red blood cells and washed with 0.9% saline solution (pH&#x02009;7.2). The peptide solutions were added to the erythrocyte suspension (1% by volume) at concentrations ranging from 6.25 to 100&#x02009;&#x003bc;M. A 0.9% saline solution and Triton X&#x02010;100 were used as negative and positive controls, respectively. After exposure, hemoglobin release was measured at 415&#x02009;nm (Park et&#x000a0;al.&#x000a0;<xref rid="cbdd70130-bib-0040" ref-type="bibr">2004</xref>). All assays were performed in triplicate. This experiment was approved by the Ethics Committee on Animal Use of the Universidade Cat&#x000f3;lica Dom Bosco under protocol number 014/2022. Three independent experiments were conducted for each condition tested.</p></sec><sec id="cbdd70130-sec-0009"><label>2.7</label><title>
<styled-content style="fixed-case" toggle="no">MTT</styled-content> Assay</title><p>To evaluate the cytotoxicity of the peptides, a 3&#x02010;(4,5&#x02010;dimethyl thiazolyl&#x02010;2)&#x02010;2,5&#x02010;diphenyltetrazolium bromide (MTT) assay was conducted, following a modified protocol derived from the methodology described in the literature (Mosmann&#x000a0;<xref rid="cbdd70130-bib-0034" ref-type="bibr">1983</xref>). RAW 264.7 macrophage cell line and fibroblasts FN1 were maintained under sterile conditions according to established instructions. Cultured in DMEM, pH range of 7.2&#x02013;7.4, (SIGMA) with 10% fetal bovine serum (SIGMA), the cells were incubated at 37&#x000b0;C in an environment of over 95% humidity and 5% CO<sub>2</sub> within a 75&#x02009;cm<sup>2</sup> (KASVI) culture flask. Upon reaching 90% confluence, the cells were detached, centrifuged at 970&#x02009;<italic toggle="yes">g</italic> for 5&#x02009;min at room temperature, and then seeded at 2&#x02009;&#x000d7;&#x02009;10<sup>5</sup>&#x02009;cells.well<sup>&#x02212;1</sup> in a 96&#x02010;well plate, according to Rezende et&#x000a0;al.&#x000a0;(<xref rid="cbdd70130-bib-1001" ref-type="bibr">2024</xref>); Buccini et&#x000a0;al.&#x000a0;(<xref rid="cbdd70130-bib-1002" ref-type="bibr">2018</xref>). Peptides at concentrations ranging from 6.25 to 100&#x02009;&#x003bc;M were added and incubated at 37&#x000b0;C for 24&#x02009;h. After discarding the supernatant, a (5&#x02009;mg.mL<sup>&#x02212;1</sup>) MTT solution (SIGMA) diluted in PBS was applied to each well. The covered plate was incubated for 4&#x02009;h at 37&#x000b0;C in darkness. Formazan crystals were solubilized using a hydrochloric acid and isopropanol solution, and cell viability percentages were determined at 540&#x02009;nm using a microplate reader (Thermo Scientific Multiskan). The results were calculated relative to the untreated cell control. The data were converted to percentage (%) according to the following equation:<disp-formula id="cbdd70130-disp-0001">
<mml:math id="jats-math-1" display="block" overflow="scroll"><mml:mrow><mml:mrow><mml:mtext>Cell viability</mml:mtext><mml:mo linebreak="goodbreak">=</mml:mo><mml:mfenced close=")" open="("><mml:mfrac><mml:mrow><mml:mi>Abs</mml:mi><mml:mspace width="0.25em"/><mml:mtext>sample</mml:mtext></mml:mrow><mml:mrow><mml:mi>Abs</mml:mi><mml:mspace width="0.25em"/><mml:mtext>positive control</mml:mtext></mml:mrow></mml:mfrac></mml:mfenced><mml:mo linebreak="goodbreak">&#x000d7;</mml:mo><mml:mn>100</mml:mn></mml:mrow></mml:mrow></mml:math>
</disp-formula>
</p></sec><sec id="cbdd70130-sec-0010"><label>2.8</label><title>Circular Dichroism (<styled-content style="fixed-case" toggle="no">CD</styled-content>) Spectrometry</title><p>CD analyses were performed using a Jasco J&#x02010;1100 spectropolarimeter (Jasco Inc., Japan) equipped with a quartz cuvette with a 1&#x02009;mm path length. The spectrum from 185 to 250&#x02009;nm was collected with a resolution step of 0.1&#x02009;nm at 100&#x02009;nm.s<sup>&#x02212;1</sup> at 25&#x000b0;C, averaging five accumulated scans for each condition. A 300&#x02009;&#x003bc;M stock solution of peptides was prepared in water and used to create a 30&#x02009;&#x003bc;M working solution. The secondary structure of the peptides was analysed in the presence of water, pH&#x02009;7.0, 50% trifluoroethanol (TFE), pH&#x02009;5.5, and 50&#x02009;mM SDS, pH&#x02009;7.5. The data were converted to molar ellipticity ([&#x003b8;]) according to the following equation:<disp-formula id="cbdd70130-disp-0002">
<mml:math id="jats-math-2" display="block" overflow="scroll"><mml:mrow><mml:mrow><mml:mfenced close="]" open="["><mml:mi mathvariant="normal">&#x003b8;</mml:mi></mml:mfenced><mml:mo linebreak="goodbreak">=</mml:mo><mml:mfrac><mml:mi mathvariant="normal">&#x003b8;</mml:mi><mml:mrow><mml:mn>10</mml:mn><mml:mo>*</mml:mo><mml:mi mathvariant="normal">C</mml:mi><mml:mo>*</mml:mo><mml:mn>1</mml:mn><mml:mo>*</mml:mo><mml:mi mathvariant="italic">nr</mml:mi></mml:mrow></mml:mfrac></mml:mrow></mml:mrow></mml:math>
</disp-formula>where &#x003b8; is the measured ellipticity in millidegrees, C is the peptide concentration (M), l is the path length of the cuvette, and nr is the number of amino acid residues. The fractional &#x003b1;&#x02010;helix content (<mml:math id="jats-math-3" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>fH</mml:mi></mml:mrow></mml:mrow></mml:math>) was estimated using the equation:<disp-formula id="cbdd70130-disp-0003">
<mml:math id="jats-math-4" display="block" overflow="scroll"><mml:mrow><mml:mrow><mml:mi mathvariant="italic">fH</mml:mi><mml:mo linebreak="goodbreak">=</mml:mo><mml:mfrac><mml:mrow><mml:mi mathvariant="normal">&#x003b8;</mml:mi><mml:mn>222</mml:mn><mml:mo>&#x02212;</mml:mo><mml:mi>&#x003b8;C</mml:mi></mml:mrow><mml:mrow><mml:mi>&#x003b8;H</mml:mi><mml:mo>&#x02212;</mml:mo><mml:mi>&#x003b8;C</mml:mi></mml:mrow></mml:mfrac></mml:mrow></mml:mrow></mml:math>
</disp-formula>where &#x003b8;C&#x02009;=&#x02009;2220&#x02013;53, and &#x003b8;H&#x02009;=&#x02009;(250&#x02009;T&#x02014;44,000) (1&#x02013;3.n), with T representing temperature in Celsius, and n being the number of amino acid residues in the peptides. The values of &#x003b8;C and &#x003b8;H represent the limit values of mean ellipticity at 222&#x02009;nm (&#x003b8;<sub>222</sub>) for the disordered and &#x003b1;&#x02010;helix conformations, respectively. The helicity percentages of the peptides were predicted by the online tool, Bestsel with a scale factor of 3.5 (<ext-link xlink:href="https://bestsel.elte.hu/index.php" ext-link-type="uri">https://bestsel.elte.hu/index.php</ext-link>).</p></sec><sec id="cbdd70130-sec-0011"><label>2.9</label><title>
<italic toggle="no">Docking</italic> Molecular</title><p>Membranes were constructed using the <italic toggle="yes">Charmm GUI</italic> membrane builder, using a ratio of 90% DPPE and 10% DPPG for gram&#x02010;negative membranes (Feng et&#x000a0;al.&#x000a0;<xref rid="cbdd70130-bib-0014" ref-type="bibr">2020</xref>). <italic toggle="yes">OpenBabel</italic> software was used to prepare the receptor and peptides (O'Boyle et&#x000a0;al.&#x000a0;<xref rid="cbdd70130-bib-0036" ref-type="bibr">2011</xref>). A grid box of 60&#x02009;&#x000d7;&#x02009;60&#x02009;&#x000d7;&#x02009;40&#x02009;&#x000c5; was defined for the top of the membranes, and 200 simulations were performed in <italic toggle="yes">AutoDock Vina</italic> (Trott and Olson&#x000a0;<xref rid="cbdd70130-bib-0048" ref-type="bibr">2010</xref>). The VinaAutomatic package was used to automate the simulations and subsequent analysis (available at <ext-link xlink:href="https://github.com/mattospedrof/VinaAutomatic" ext-link-type="uri">https://github.com/mattospedrof/VinaAutomatic</ext-link>). For interaction analysis, the protein&#x02010;ligand interaction profiler web server was used (Adasme et&#x000a0;al.&#x000a0;<xref rid="cbdd70130-bib-0001" ref-type="bibr">2021</xref>).</p></sec><sec id="cbdd70130-sec-0012"><label>2.10</label><title>Statistical Analysis</title><p>The statistical significance of the experimental results was determined using a one&#x02010;way Student's <italic toggle="yes">t</italic>&#x02010;test or one&#x02010;way analysis of variance (ANOVA), followed by Dunnett's multiple comparison test. Values of <italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.05 were considered statistically significant. GraphPad Prism version 8.0 was employed for all statistical analyses.</p></sec></sec><sec sec-type="results" id="cbdd70130-sec-0013"><label>3</label><title>Results</title><sec id="cbdd70130-sec-0014"><label>3.1</label><title>Rational Design, Validation of Peptides and Synthesis</title><p>The three&#x02010;dimensional structure of papain (PDB 9PAP), specifically the segment from residues 26 to 43, was employed as a scaffold for the rational design of (Tables&#x000a0;<xref rid="cbdd70130-supitem-0002" ref-type="supplementary-material">S1&#x02013;S4</xref>) peptides (Figure&#x000a0;<xref rid="cbdd70130-fig-0001" ref-type="fig">1A</xref>). This selected portion of the enzyme exhibits critical characteristics necessary for an AMP, including the presence of amphipathic &#x003b1;&#x02010;helices and residues such as tryptophan and arginine, which enhance interactions with bacterial membranes (Chan et&#x000a0;al.&#x000a0;<xref rid="cbdd70130-bib-0007" ref-type="bibr">2006</xref>; Huang et&#x000a0;al.&#x000a0;<xref rid="cbdd70130-bib-0022" ref-type="bibr">2010</xref>). The model peptide WG18 comprises 18 amino acid residues (<sup>26</sup>WAFSAVVTIEGIIKIRTG<sup>43</sup>) with a net charge of +1, a hydrophobic moment of 0.188, hydrophobicity of 67%, and a defined &#x003b1;&#x02010;helical structure. Following reorganization, the WK&#x02010;MAP1 peptide (WAKSAVKAIEGIIKILTK) displayed a net charge of +3, a hydrophobic moment of 0.638, hydrophobicity of 49%, and a defined &#x003b1;&#x02010;helical structure. Similarly, WG&#x02010;MAP2 (WAKSAVKAIRGIIKIITG) demonstrated a net charge of +4, a hydrophobic moment of 0.613, hydrophobicity of 53%, and a defined &#x003b1;&#x02010;helical structure (Figure&#x000a0;<xref rid="cbdd70130-fig-0001" ref-type="fig">1B</xref>). Helical wheel plotting using HeliQuest revealed that WG18 lacked an organized distribution of polar and nonpolar amino acids. In contrast, the analogues showed a reorganization of polar and nonpolar residues on separate faces, imparting amphipathic properties to the peptides (Figure&#x000a0;<xref rid="cbdd70130-fig-0001" ref-type="fig">1C</xref>). The analogue peptides maintained 72% identity with the model peptide WG18 (Table&#x000a0;<xref rid="cbdd70130-tbl-0001" ref-type="table">1</xref>).</p><fig position="float" fig-type="FIGURE" id="cbdd70130-fig-0001"><label>FIGURE 1</label><caption><p>Three&#x02010;dimensional representation of the (A) papain enzyme (PDB: 9PAP) with the model portion used for designing the analogues highlighted in purple. (B) Three&#x02010;dimensional representation of the peptides. (C) Schiffer&#x02010;Edmundson helical wheel using HeliQuest, showing increased hydrophobic moments in the two analogues compared to the model &#x003b1;&#x02010;helix, represented by the arrows in the center. Hydrophobic faces are also represented by the yellow and gray amino acids at the bottom of the two analogues.</p></caption><graphic xlink:href="CBDD-105-e70130-g002" position="anchor" id="jats-graphic-3"/></fig><table-wrap position="float" id="cbdd70130-tbl-0001" content-type="TABLE"><label>TABLE 1</label><caption><p>Physicochemical characteristics of the native peptide and its analogs.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1">Name</th><th align="center" valign="bottom" rowspan="1" colspan="1">Sequence</th><th align="center" valign="bottom" rowspan="1" colspan="1">
<italic toggle="yes">Z</italic>+</th><th align="center" valign="bottom" rowspan="1" colspan="1">
<italic toggle="yes">Z</italic>&#x02212;</th><th align="center" valign="bottom" rowspan="1" colspan="1">
<italic toggle="yes">Z</italic>*</th><th align="center" valign="bottom" rowspan="1" colspan="1">H</th><th align="center" valign="bottom" rowspan="1" colspan="1">&#x003bc;H</th><th align="center" valign="bottom" rowspan="1" colspan="1">NP (%)</th><th align="center" valign="bottom" rowspan="1" colspan="1">ID (%)</th><th align="center" valign="bottom" rowspan="1" colspan="1">MW (Da)</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">WG18</td><td align="center" valign="top" rowspan="1" colspan="1">WAFSAVVTIEGIIKIRTG</td><td align="center" valign="top" rowspan="1" colspan="1">+2</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;1</td><td align="center" valign="top" rowspan="1" colspan="1">+1</td><td align="center" valign="top" rowspan="1" colspan="1">0.188</td><td align="center" valign="top" rowspan="1" colspan="1">0.674</td><td align="center" valign="top" rowspan="1" colspan="1">55.54</td><td align="center" valign="top" rowspan="1" colspan="1">100</td><td align="center" valign="top" rowspan="1" colspan="1">1961.3</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">WK&#x02010;MAP1</td><td align="center" valign="top" rowspan="1" colspan="1">WAKSAVKAIEGIIKILTK</td><td align="center" valign="top" rowspan="1" colspan="1">+4</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;1</td><td align="center" valign="top" rowspan="1" colspan="1">+3</td><td align="center" valign="top" rowspan="1" colspan="1">0.638</td><td align="center" valign="top" rowspan="1" colspan="1">0.496</td><td align="center" valign="top" rowspan="1" colspan="1">55.56</td><td align="center" valign="top" rowspan="1" colspan="1">72</td><td align="center" valign="top" rowspan="1" colspan="1">1969.4</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">WG&#x02010;MAP2</td><td align="center" valign="top" rowspan="1" colspan="1">WAKSAVKAIRGIIKIITG</td><td align="center" valign="top" rowspan="1" colspan="1">+4</td><td align="center" valign="top" rowspan="1" colspan="1">0</td><td align="center" valign="top" rowspan="1" colspan="1">+4</td><td align="center" valign="top" rowspan="1" colspan="1">0.613</td><td align="center" valign="top" rowspan="1" colspan="1">0.536</td><td align="center" valign="top" rowspan="1" colspan="1">55.56</td><td align="center" valign="top" rowspan="1" colspan="1">72</td><td align="center" valign="top" rowspan="1" colspan="1">1925.3</td></tr></tbody></table><table-wrap-foot id="cbdd70130-ntgp-0002"><fn id="cbdd70130-note-0002"><p>Abbreviations: ID, identify; MW, molecular weight; NP, nonpolar; <italic toggle="yes">Z</italic>*, net charge; <italic toggle="yes">Z</italic>&#x02212;, negative charged; <italic toggle="yes">Z</italic>+, positive charged; &#x003bc;H, hydrophobicity moment; hydrophobicity.</p></fn></table-wrap-foot></table-wrap><p>To validate the three&#x02010;dimensional models generated by AlphaFold, the MolProbity software was used to generate Ramachandran plots. The analysis demonstrated that the phi (&#x003c6;) and psi (&#x003c8;) torsion angles of the amino acid residues in WG18, WK&#x02010;MAP1, and WG&#x02010;MAP2 were predominantly located within allowed regions, with 98% corresponding to secondary conformations, particularly &#x003b1;&#x02010;helices. The QMEAN&#x02010;SwissModel tool was used to assess the reliability of AlphaFold&#x02010;generated models, providing <italic toggle="yes">Z</italic>&#x02010;scores of 0.67&#x02009;&#x000b1;&#x02009;0.12 for WG18, 0.69&#x02009;&#x000b1;&#x02009;0.12 for WK&#x02010;MAP1, and 0.59&#x02009;&#x000b1;&#x02009;0.12 for WG&#x02010;MAP2, indicating varying levels of model reliability. The antimicrobial potential of the peptides was evaluated using artificial intelligence programs, as shown in Table&#x000a0;<xref rid="cbdd70130-supitem-0002" ref-type="supplementary-material">S2</xref>. The model peptide WG18 showed limited antimicrobial and anticancer potential, with a low probability of being an AMP (0.677 in SVM). Conversely, WK&#x02010;MAP1 exhibited high antimicrobial potential across all classifiers, with a probability of 0.989 in SVM. Similarly, WG&#x02010;MAP2 demonstrated strong antimicrobial activity, achieving a probability of 0.975 in RF. None of the peptides showed significant cytotoxicity (Table&#x000a0;<xref rid="cbdd70130-tbl-0002" ref-type="table">2</xref>).</p><table-wrap position="float" id="cbdd70130-tbl-0002" content-type="TABLE"><label>TABLE 2</label><caption><p>Functional predictions for WG18, WK&#x02010;MAP1, and WG&#x02010;MAP2 peptides based on the CAMPR4, Sense the Moment, HemoPI 2.0, and ToxinPred servers.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="2" valign="bottom" colspan="1">Peptide ID</th><th align="center" colspan="3" valign="bottom" rowspan="1">CAMPr4</th><th align="center" rowspan="2" valign="bottom" colspan="1">Sense the moment (ML)</th><th align="center" rowspan="2" valign="bottom" colspan="1">HemoPI 2.0 SVM</th><th align="center" rowspan="2" valign="bottom" colspan="1">ToxinPred SVM</th></tr><tr style="border-bottom:solid 1px #000000"><th align="center" valign="bottom" rowspan="1" colspan="1">SVM</th><th align="center" valign="bottom" rowspan="1" colspan="1">RF</th><th align="center" valign="bottom" rowspan="1" colspan="1">ANN</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">WG18</td><td align="center" valign="top" rowspan="1" colspan="1">0.677</td><td align="center" valign="top" rowspan="1" colspan="1">0.728</td><td align="center" valign="top" rowspan="1" colspan="1">NAMP</td><td align="center" valign="top" rowspan="1" colspan="1">0.1656</td><td align="center" valign="top" rowspan="1" colspan="1">Hemolytic</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;1.41</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">WK&#x02010;MAP1</td><td align="center" valign="top" rowspan="1" colspan="1">0.989</td><td align="center" valign="top" rowspan="1" colspan="1">0.9475</td><td align="center" valign="top" rowspan="1" colspan="1">AMP</td><td align="center" valign="top" rowspan="1" colspan="1">1.2510</td><td align="center" valign="top" rowspan="1" colspan="1">Nonhemolytic</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;1.38</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">WG&#x02010;MAP2</td><td align="center" valign="top" rowspan="1" colspan="1">0.967</td><td align="center" valign="top" rowspan="1" colspan="1">0.975</td><td align="center" valign="top" rowspan="1" colspan="1">AMP</td><td align="center" valign="top" rowspan="1" colspan="1">1.2434</td><td align="center" valign="top" rowspan="1" colspan="1">Nonhemolytic</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;1.10</td></tr></tbody></table><table-wrap-foot id="cbdd70130-ntgp-0003"><fn id="cbdd70130-note-0003"><p>
<italic toggle="yes">Note:</italic> The parameters include prediction scores generated by machine learning classifiers: support vector machine (SVM), random forest (RF), and artificial neural network (ANN). Peptides are classified as AMP (antimicrobial peptide) or NAMP (nonantimicrobial peptide) according to each tool's criteria.</p></fn></table-wrap-foot></table-wrap><p>Additionally, the ToxinPred program predicted molecular masses consistent with synthesis values: 1960.30&#x02009;Da for WK&#x02010;MAP1, 1968.40&#x02009;Da for WG&#x02010;MAP2, and 1924.30&#x02009;Da for WG18. These peptides were chemically synthesized with 95% purity, and their synthesized masses closely aligned with the predictions (Table&#x000a0;<xref rid="cbdd70130-tbl-0001" ref-type="table">1</xref>). Both peptides were diluted in ultrapure water to prepare stock solutions and stored at &#x02212;20&#x000b0;C for subsequent vitro assays. These validations and detailed analyses support the viability of these peptides as candidates for next&#x02010;generation antimicrobial agents.</p></sec><sec id="cbdd70130-sec-0015"><label>3.2</label><title>Antibacterial Assays</title><p>The peptides WG18, WK&#x02010;MAP1, and WG&#x02010;MAP2 were evaluated against two <styled-content style="fixed-case" toggle="no">
<italic toggle="no">K. pneumoniae</italic>
</styled-content> strains: ATCC 13883 (a standard susceptible strain) and KPC&#x02009;+&#x02009;001450421 (a carbapenem&#x02010;resistant, KPC&#x02010;producing strain). In&#x000a0;vitro assays were performed using peptide concentrations ranging from 6.25 to 100&#x02009;&#x003bc;M, with bacterial growth assessed relative to the untreated control (C+). The model peptide WG18 exhibited partial inhibitory activity at 100&#x02009;&#x003bc;M against both strains. WK&#x02010;MAP1 showed partial inhibition against the ATCC strain and achieved a MIC of 100&#x02009;&#x003bc;M against the KPC strain. WG&#x02010;MAP2 demonstrated inhibitory activity against both strains, with MIC values of 50&#x02009;&#x003bc;M for the ATCC strain and 25&#x02009;&#x003bc;M for the KPC strain (Figure&#x000a0;<xref rid="cbdd70130-fig-0002" ref-type="fig">2</xref>). Additionally, MBC was observed only for WG&#x02010;MAP2, with values of 100&#x02009;&#x003bc;M for the ATCC strain and 50&#x02009;&#x003bc;M for the KPC strain (Figure&#x000a0;<xref rid="cbdd70130-supitem-0001" ref-type="supplementary-material">S2</xref>).</p><fig position="float" fig-type="FIGURE" id="cbdd70130-fig-0002"><label>FIGURE 2</label><caption><p>Minimal inhibitory concentration of (A) <styled-content style="fixed-case" toggle="no">
<italic toggle="no">Klebsiella pneumoniae</italic>
</styled-content> (ATCC 13883) and (B) <styled-content style="fixed-case" toggle="no">
<italic toggle="no">K. pneumoniae</italic>
</styled-content> (KPC&#x02009;+&#x02009;001450421) for the peptides WG18, WK&#x02010;MAP1, and WG&#x02010;MAP2. Results are presented as optical density at OD<sub>600&#x02009;nm</sub> with values derived from experiments performed in triplicate. Statistical analysis was performed using two&#x02010;way ANOVA followed by Tukey test (****) <italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.001.</p></caption><graphic xlink:href="CBDD-105-e70130-g003" position="anchor" id="jats-graphic-5"/></fig></sec><sec id="cbdd70130-sec-0016"><label>3.3</label><title>Biofilm Formation Assays</title><p>The biofilm formation inhibition assay for the three peptides (WG18, WK&#x02010;MAP1, and WG&#x02010;MAP2) was performed against two <styled-content style="fixed-case" toggle="no">
<italic toggle="no">K. pneumoniae</italic>
</styled-content> strains: the ATCC reference strain and a KPC&#x02010;producing MDR strain. The peptides were tested at the same concentrations used in the MIC assays. The results are expressed as optical density at 595&#x02009;nm (OD595) and transformed into percentage, indicating biofilm formation. WG18 showed no significant inhibitory effect on biofilm formation in the ATCC strain, even at the highest concentrations tested.</p><p>In contrast, WK&#x02010;MAP1 significantly inhibited biofilm formation in the ATCC strain, with complete inhibition observed at 50&#x02009;&#x003bc;M. WG&#x02010;MAP2 demonstrated a gradual reduction in biofilm formation at 25&#x02009;&#x003bc;M. Similarly, WG18 exhibited no notable inhibition of biofilm formation in the KPC strain at any tested concentration. WK&#x02010;MAP1 was less effective against the KPC strain, achieving complete inhibition only at 100&#x02009;&#x003bc;M. In the case of WG&#x02010;MAP2, there was inhibition of biofilm formation in the KPC strain at 50&#x02009;&#x003bc;M, indicating effective disruption of biofilm development (Figure&#x000a0;<xref rid="cbdd70130-fig-0003" ref-type="fig">3</xref>).</p><fig position="float" fig-type="FIGURE" id="cbdd70130-fig-0003"><label>FIGURE 3</label><caption><p>Minimal inhibitory concentration of biofilm formation of (A) <styled-content style="fixed-case" toggle="no">
<italic toggle="no">Klebsiella pneumoniae</italic>
</styled-content> (ATCC 13883) and (B) <styled-content style="fixed-case" toggle="no">
<italic toggle="no">K. pneumoniae</italic>
</styled-content> (KPC&#x02009;+&#x02009;001450421) for the peptides WG18, WK&#x02010;MAP1, and WG&#x02010;MAP2. Results are performed in triplicate, and statistical analysis using two&#x02010;way ANOVA followed by Tukey test (****) <italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.001.</p></caption><graphic xlink:href="CBDD-105-e70130-g004" position="anchor" id="jats-graphic-7"/></fig></sec><sec id="cbdd70130-sec-0017"><label>3.4</label><title>Cytotoxicity Activity</title><p>The hemolytic activity of the peptides WK&#x02010;MAP1 and WG&#x02010;MAP2 was evaluated by measuring hemolysis percentages in murine erythrocytes. The results (Figure&#x000a0;<xref rid="cbdd70130-fig-0004" ref-type="fig">4</xref>) demonstrate that both peptides exhibited low hemolytic activity, with significant effects observed only at the highest concentration tested (100&#x02009;&#x003bc;M). For WK&#x02010;MAP1, hemolysis reached approximately 12%, whereas WG&#x02010;MAP2 caused around 18% hemolysis at 100&#x02009;&#x003bc;M, indicating their relative safety for red blood cells at lower concentrations.</p><fig position="float" fig-type="FIGURE" id="cbdd70130-fig-0004"><label>FIGURE 4</label><caption><p>Hemolytic activity against murine erythrocytes for the peptide analogs WK&#x02010;MAP1 and WG&#x02010;MAP2 at different concentrations with values derived from experiments performed in triplicate. Statistical analysis was performed using two&#x02010;way ANOVA followed by Tukey test (****) <italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.001.</p></caption><graphic xlink:href="CBDD-105-e70130-g007" position="anchor" id="jats-graphic-9"/></fig><p>In addition to hemolytic activity, the cytotoxic effects were evaluated through cell viability assays in the FN1 and Raw cell lines. For FN1 cells, WK&#x02010;MAP1 also exhibited significant cytotoxicity in a dose&#x02010;dependent manner, with viability remaining around ~20%&#x02013;25% at concentrations of 100 and 50&#x02009;&#x003bc;M, respectively. However, its cytotoxicity decreased from 25&#x02009;&#x003bc;M, where viable cells reached ~45%, ultimately achieving 100% viability at 6.25&#x02009;&#x003bc;M. Lastly, WG&#x02010;MAP2 displayed moderate cytotoxicity against FN1 cells, maintaining ~50% cell viability at concentrations between 100 and 25&#x02009;&#x003bc;M, with viability increasing to ~90% at 6.25&#x02009;&#x003bc;M (Figure&#x000a0;<xref rid="cbdd70130-fig-0005" ref-type="fig">5A</xref>). Regarding Raw cells, WK&#x02010;MAP1 significantly reduced Raw cell viability in a dose&#x02010;dependent manner. At 100&#x02009;&#x003bc;M, the peptide resulted in approximately ~10% viable cells. Starting at 25&#x02009;&#x003bc;M, the viability reached ~50%, and at 12.5&#x02009;&#x003bc;M, the peptide lost most of its cytotoxicity, with viable cells increasing to ~90% (Figure&#x000a0;<xref rid="cbdd70130-fig-0005" ref-type="fig">5B</xref>). In contrast, WG&#x02010;MAP2 had minimal impact on Raw cell viability, maintaining ~90% viable cells even at 100&#x02009;&#x003bc;M.</p><fig position="float" fig-type="FIGURE" id="cbdd70130-fig-0005"><label>FIGURE 5</label><caption><p>Cytotoxicity effect of the analog peptides WK&#x02010;MAP1 and WG&#x02010;MAP2 against cell line. (A) Cell viability of FN1 (human fibroblast) (B) cell viability of RAW (murine macrophages) with values derived from experiments performed in triplicate. Statistical analysis was performed using two&#x02010;way ANOVA followed by Tukey test (****) <italic toggle="yes">p&#x02009;&#x0003c;</italic>&#x02009;0.001.</p></caption><graphic xlink:href="CBDD-105-e70130-g008" position="anchor" id="jats-graphic-11"/></fig><p>The model peptide WG18 was not included in the cytotoxicity evaluations. This decision was based on the peptide's limited antimicrobial activity, as previously demonstrated in MIC and biofilm inhibition assays. Given its suboptimal performance in these critical tests, WG18 was deemed less relevant for cytotoxic analyses, as the primary focus of this study was on the optimized analogues, WK&#x02010;MAP1, and WG&#x02010;MAP2. These analogues were specifically designed to enhance antimicrobial efficacy and reduce cytotoxicity, making them the most promising candidates for further evaluation. This approach aligns with the study's objective to prioritize the exploration of analogues with improved therapeutic potential while using the model peptide WG18 solely as a reference scaffold. Such a strategy is commonly adopted in peptide design studies (Matali&#x00144;ska et&#x000a0;al.&#x000a0;<xref rid="cbdd70130-bib-0032" ref-type="bibr">2020</xref>), where the focus is directed toward derivatives that exhibit superior performance.</p></sec><sec id="cbdd70130-sec-0018"><label>3.5</label><title>
<styled-content style="fixed-case" toggle="no">CD</styled-content> Spectrometry</title><p>The conformational properties of WK&#x02010;MAP1 and WG&#x02010;MAP2 were analyzed using CD spectrometry under conditions simulating aqueous environments and anionic membranes (Figure&#x000a0;<xref rid="cbdd70130-fig-0006" ref-type="fig">6</xref>). In an aqueous solution, WK&#x02010;MAP1 exhibited a random coil structure, characterized by a negative band between 195 and 208&#x02009;nm and the absence of a signal near ~222&#x02009;nm. Upon incubation with 50% TFE and 100&#x02009;mM SDS, the CD spectrum of WK&#x02010;MAP1 underwent notable changes, showing a positive band around 192&#x02009;nm and negative bands at 208 and 222&#x02009;nm. These alterations suggest a structural transition indicative of &#x003b1;&#x02010;helix formation (Kelly and Price&#x000a0;<xref rid="cbdd70130-bib-0024" ref-type="bibr">2006</xref>). Similarly, WG&#x02010;MAP2 initially displayed a random coil conformation in an aqueous solution. However, when incubated with 50% TFE and 100&#x02009;mM SDS, WG&#x02010;MAP2 exhibited a positive band near 192&#x02009;nm and negative bands at 208 and 222&#x02009;nm, indicating a conformational transition consistent with &#x003b1;&#x02010;helix structuring (Greenfield&#x000a0;<xref rid="cbdd70130-bib-0018" ref-type="bibr">2006</xref>).</p><fig position="float" fig-type="FIGURE" id="cbdd70130-fig-0006"><label>FIGURE 6</label><caption><p>Conformational changes of synthetic peptides evaluated by circular dichroism in aqueous, TFE, and SDS environments. Spectra of (A) WK&#x02010;MAP1 and (B) WG&#x02010;MAP2 in water (green line), 50% TFE (red line), and 50&#x02009;mM SDS (blue line). All spectra were collected at 25&#x000b0;C.</p></caption><graphic xlink:href="CBDD-105-e70130-g006" position="anchor" id="jats-graphic-13"/></fig></sec><sec id="cbdd70130-sec-0019"><label>3.6</label><title>Molecular Docking</title><p>Model selection for structural analysis was based on the frequency of interaction energies observed across 207 molecular dynamics simulations (Figure&#x000a0;<xref rid="cbdd70130-fig-0007" ref-type="fig">7</xref>). The most frequently occurring binding energies for WG&#x02010;18, WK&#x02010;MAP1, and WG&#x02010;MAP2 were &#x02212;4.8, &#x02212;4.6, and &#x02212;4.4&#x02009;kcal&#x000b7;mol<sup>&#x02212;1</sup>, respectively. These values correlate with the interaction profiles and in&#x000a0;vitro findings. WG&#x02010;18 demonstrated affinity for the membrane mimetic, as indicated by the interaction data, yet this did not translate into significant antimicrobial activity. In contrast, WK&#x02010;MAP1 exhibited both membrane affinity and effective antimicrobial activity, particularly against KPC&#x02010;producing and biofilm&#x02010;forming bacteria. WG&#x02010;MAP2 not only showed strong membrane interaction but also yielded the most potent in&#x000a0;vitro activity, with observed MIC values against both planktonic and biofilm&#x02010;forming ATCC and KPC strains.</p><fig position="float" fig-type="FIGURE" id="cbdd70130-fig-0007"><label>FIGURE 7</label><caption><p>Molecular docking of the peptides interacting with gram&#x02010;negative phospholipid bacteria membranes. (A) WG18 (B) affinity energy frequency for the WG18 model (C) WK&#x02010;MAP1 (D) affinity energy frequency for the WK&#x02010;MAP1 model (E) WG&#x02010;MAP2 (F) affinity energy frequency for the WG&#x02010;MAP2 model.</p></caption><graphic xlink:href="CBDD-105-e70130-g005" position="anchor" id="jats-graphic-15"/></fig><p>Based on in silico results for the protein&#x02013;ligand complex involving WG18 and a membrane mimetic model, multiple noncovalent interactions were identified, highlighting the peptide's binding affinity and specificity toward phospholipid components (Figure&#x000a0;<xref rid="cbdd70130-fig-0007" ref-type="fig">7</xref>). WG18 exhibited several hydrophobic interactions with nonpolar residues, including tryptophan (Trp), alanine (Ala), phenylalanine (Phe), valine (Val), threonine (Thr), isoleucine (Ile), glutamate (Glu), arginine (Arg), and glycine (Gly). These interactions, with interatomic distances ranging from approximately 3.1&#x02013;4.5&#x02009;&#x000c5;, suggest that the peptide is accommodated within a hydrophobic pocket, facilitating van der Waals contacts that enhance binding stability.</p><p>Two significant hydrogen bonds were observed: one with arginine (Arg) at a donor&#x02013;acceptor distance of 3.7&#x02009;&#x000c5; and another with threonine (Thr) at 3.2&#x02009;&#x000c5;. These interactions, characterized by favorable donor angles, play a critical role in stabilizing the ligand orientation within the binding site and enhancing molecular specificity. In addition, one electrostatic interaction was detected between the ligand's carboxylate and the positively charged residues lysine (Lys), with a distance of 4.8&#x02009;&#x000c5;.</p><p>Similarly, the WK&#x02010;MAP1 analogue exhibited multiple noncovalent interactions, including hydrophobic contacts with Trp, Ala, Lys, Val, Ile, and Glu residues. These interactions, occurring at distances ranging from 2.9 to 4.0&#x02009;&#x000c5;, suggest that the peptide is likewise stabilized within a hydrophobic environment. Two prominent hydrogen bonds were identified with threonine residues at 3.0 and 4.0&#x02009;&#x000c5;, respectively, both contributing to accurate ligand orientation and increased binding specificity. Additionally, four electrostatic interactions involving lysine residues, with interatomic distances ranging from 3.6 to 4.3&#x02009;&#x000c5;, further supported membrane anchoring and overall complex stability.</p><p>Finally, the WG&#x02010;MAP2 peptide analogue established extensive hydrophobic interactions with nonpolar residues, including Trp, Ala, Val, Lys, Ile, and Arg, with interatomic distances ranging from 3.4 to 3.9&#x02009;&#x000c5;. Two significant hydrogen bonds were identified involving the amino acids Ile and Thr, acting as acceptor and donor, respectively, with distances of 3.2 and 3.1&#x02009;&#x000c5;. These interactions contribute to the correct orientation and stabilization of the ligand within the binding interface. Moreover, electrostatic interactions were observed involving a single arginine residue engaging in two interactions with the ligand DPP, with distances of 4.1 and 4.3&#x02009;&#x000c5;. These dual electrostatic contacts highlight the critical role of Arg in anchoring the peptide and promoting stable complex formation.</p></sec></sec><sec sec-type="discussion" id="cbdd70130-sec-0020"><label>4</label><title>Discussion</title><p>The findings of this study highlight the potential of the peptides WK&#x02010;MAP1 and WG&#x02010;MAP2 as promising candidates for novel antimicrobial therapies. The importance of AMPs in addressing bacterial resistance is widely recognized, as outlined in the introduction of this research (Hetta et&#x000a0;al.&#x000a0;<xref rid="cbdd70130-bib-0021" ref-type="bibr">2024</xref>; Erriah et&#x000a0;al.&#x000a0;<xref rid="cbdd70130-bib-0012" ref-type="bibr">2025</xref>). These peptides provide a viable alternative to traditional antibiotics, particularly considering the alarming rise of MDR pathogens.</p><p>The helical wheel projections reveal a distinct amphipathic &#x003b1;&#x02010;helical structure in WK&#x02010;MAP1 and WG&#x02010;MAP2, characterized by a clear segregation of hydrophobic and positively charged residues. This amphipathicity is critical for membrane interaction and disruption, which likely enhances their antimicrobial and antibiofilm activities (Yeaman and Yount&#x000a0;<xref rid="cbdd70130-bib-0058" ref-type="bibr">2003</xref>). In contrast, WG18 displays a less pronounced amphipathic pattern, with a more scattered distribution of charged and hydrophobic residues, potentially resulting in reduced membrane affinity and lower bioactivity. Additionally, the presence of multiple lysine and arginine residues on one face of the helix in WK&#x02010;MAP1 and WG&#x02010;MAP2 may increase electrostatic interactions with negatively charged bacterial membranes, further promoting insertion and disruption. Therefore, the structural organization of side chains and the helical amphipathicity observed in WK&#x02010;MAP1 and WG&#x02010;MAP2 provide a rational explanation for their enhanced activity compared to WG18.</p><p>The &#x003b1;&#x02010;helical conformation observed through CD spectrometry emerged as an essential feature in the analogue peptides WK&#x02010;MAP1 and WG&#x02010;MAP2, demonstrating their potential to interact efficiently with bacterial membranes (Kelly and Price&#x000a0;<xref rid="cbdd70130-bib-0024" ref-type="bibr">2006</xref>; Greenfield&#x000a0;<xref rid="cbdd70130-bib-0018" ref-type="bibr">2006</xref>).</p><p>In antimicrobial assessments, WK&#x02010;MAP1 exhibited superior efficacy against <styled-content style="fixed-case" toggle="no">
<italic toggle="no">K. pneumoniae</italic>
</styled-content> KPC+, a MDR pathogen, with a MIC of 25&#x02009;&#x003bc;M. Conversely, WG&#x02010;MAP2 demonstrated efficacy against both tested strains, ATCC and KPC+, with MIC values of 50 and 100&#x02009;&#x003bc;M, respectively. These findings highlight the significance of amphipathic properties and positive charges in these peptides, which facilitate interactions with anionically charged bacterial membranes (Souza E Silva et&#x000a0;al.&#x000a0;<xref rid="cbdd70130-bib-1003" ref-type="bibr">2022</xref>). Previous studies have shown that structural reorganization to enhance amphipathicity significantly improves antimicrobial activity (Batoni et&#x000a0;al.&#x000a0;<xref rid="cbdd70130-bib-1004" ref-type="bibr">2016</xref>; Erriah et&#x000a0;al.&#x000a0;<xref rid="cbdd70130-bib-1005" ref-type="bibr">2024</xref>).</p><p>The differential activity observed between the carbapenem&#x02010;sensitive <styled-content style="fixed-case" toggle="no">
<italic toggle="no">K. pneumoniae</italic>
</styled-content> ATCC 13883 and the carbapenem&#x02010;resistant KPC&#x02010;producing strain likely reflects structural and physiological adaptations associated with resistance (Yeaman and Yount&#x000a0;<xref rid="cbdd70130-bib-0058" ref-type="bibr">2003</xref>). Although carbapenemase production does not directly alter membrane phospholipid composition, it is often accompanied by decreased porin expression, increased efflux pump activity, and reduced outer membrane permeability, all of which contribute to diminished antimicrobial susceptibility (Pag&#x000e8;s et&#x000a0;al.&#x000a0;<xref rid="cbdd70130-bib-0038" ref-type="bibr">2008</xref>). Rational peptide modifications, such as increasing cationic charge or optimizing hydrophobicity and amphipathicity, can enhance activity against resistant strains by improving interactions with altered membranes. These findings support structure&#x02010;based optimization strategies to overcome resistance and enhance peptide efficacy across diverse bacterial phenotypes (Mahlapuu et&#x000a0;al.&#x000a0;<xref rid="cbdd70130-bib-0030" ref-type="bibr">2016</xref>).</p><p>Meropenem was employed as the positive control in the biofilm inhibition assays due to its well&#x02010;documented efficacy against bacterial infections, including those associated with biofilm formation. This broad&#x02010;spectrum &#x003b2;&#x02010;lactam antibiotic, belonging to the carbapenem class, exhibits potent bactericidal activity by targeting penicillin&#x02010;binding proteins (PBPs), which are essential for the final stages of peptidoglycan cross&#x02010;linking. Inhibition of these PBPs disrupts cell wall synthesis, leading to structural instability, osmotic imbalance, and eventual cell lysis (Martinez et&#x000a0;al.&#x000a0;<xref rid="cbdd70130-bib-0031" ref-type="bibr">2025</xref>). Its inclusion as a positive control is supported by previous studies demonstrating meropenem's activity in experimental models of biofilm formation, particularly involving pathogens such as <styled-content style="fixed-case" toggle="no">
<italic toggle="no">Pseudomonas aeruginosa</italic>
</styled-content> (Santosaningsih et&#x000a0;al.&#x000a0;<xref rid="cbdd70130-bib-0043" ref-type="bibr">2024</xref>). <styled-content style="fixed-case" toggle="no">
<italic toggle="no">K. pneumoniae</italic>
</styled-content>, known for its strong biofilm&#x02010;forming capacity and increased antibiotic resistance, further justifies the use of meropenem as a benchmark compound to assess the biofilm&#x02010;inhibitory properties of novel agents in&#x000a0;vitro (Ribera et&#x000a0;al.&#x000a0;<xref rid="cbdd70130-bib-1006" ref-type="bibr">2019</xref>).</p><p>Interestingly, the amino acid tryptophan (Trp) is encoded by a single nonredundant codon (UGG) (Barik&#x000a0;<xref rid="cbdd70130-bib-0004" ref-type="bibr">2020</xref>). This unique encoding suggests that the presence of Trp in a protein or peptide is significant, as its biosynthesis incurs the highest cost of all amino acids (Barik&#x000a0;<xref rid="cbdd70130-bib-0004" ref-type="bibr">2020</xref>). Trp is classified as hydrophobic due to its uncharged side chain; however, it is not embedded in the hydrocarbon region of lipid bilayers. Instead, it is typically positioned toward the hydrophilic side (Mishra et&#x000a0;al.&#x000a0;<xref rid="cbdd70130-bib-0033" ref-type="bibr">2018</xref>). The side chain of Trp may influence the lipid membrane, thereby contributing to the antibacterial activity of peptides (Feng et&#x000a0;al.&#x000a0;<xref rid="cbdd70130-bib-0014" ref-type="bibr">2020</xref>). It is well established that for a peptide to exhibit potent antimicrobial activity, an increased positive charge and organized amphipathicity are essential for effective interaction with bacterial membranes. Additionally, a hydrophobicity of approximately 50% is critical to minimizing cytotoxicity (Silva et&#x000a0;al.&#x000a0;<xref rid="cbdd70130-bib-0045" ref-type="bibr">2023</xref>).</p><p>A relevant finding was the biofilm inhibition activity exhibited by the analogue peptides. Although WG18 had no significant impact, WK&#x02010;MAP1 and WG&#x02010;MAP2 effectively reduced biofilm formation at concentrations above 50&#x02009;&#x003bc;M, particularly against the ATCC strain. Biofilms represent a substantial clinical challenge, protecting bacteria from both antimicrobial agents and the host immune system (Roque&#x02010;Borda et&#x000a0;al.&#x000a0;<xref rid="cbdd70130-bib-0042" ref-type="bibr">2025</xref>). The divergent trend observed between planktonic bacterial suspensions and biofilms is due to their distinct structural and physiological properties. Planktonic cells, being free&#x02010;floating and metabolically active, are more susceptible to antimicrobial agents, which is reflected in lower MIC values (Hall and Mah&#x000a0;<xref rid="cbdd70130-bib-0019" ref-type="bibr">2017</xref>). In contrast, biofilm&#x02010;forming bacteria are embedded in a protective extracellular matrix, exhibit reduced metabolic activity, and express resistance&#x02010;related genes, leading to significantly higher MBIC values. This difference highlights the need for both MIC and MBIC assays, especially in clinical settings involving chronic or device&#x02010;associated infections (Hall and Mah&#x000a0;<xref rid="cbdd70130-bib-0019" ref-type="bibr">2017</xref>).</p><p>Therefore, the observed divergence in antimicrobial susceptibility trends between planktonic and biofilm states underscores the necessity of employing both MIC and MBIC assays when evaluating antimicrobial efficacy, particularly in clinical contexts involving biofilm&#x02010;associated infections such as those linked to indwelling medical devices, chronic wounds, and mucosal surfaces. This distinction is critical for guiding effective therapeutic strategies and accurately interpreting in&#x000a0;vitro antimicrobial testing outcomes. These results suggest that the designed peptides could play a pivotal role in preventing biofilm&#x02010;associated infections.</p><p>Regarding cytotoxicity, the analogue peptides exhibited low hemolytic activity in murine erythrocytes and limited cytotoxic effects in cell lines. The cytotoxic profiles of WK&#x02010;MAP1 and WG&#x02010;MAP2 peptides exhibited distinct behaviors across FN1 and RAW cell lines, highlighting their differential bioactivities and potential selectivity. WK&#x02010;MAP1 demonstrated potent cytotoxicity against FN1 cells in a dose&#x02010;dependent manner, with cell viability significantly reduced to approximately 25% at higher concentrations. This effect decreased progressively with lower concentrations, reaching full viability at 6.25&#x02009;&#x003bc;M. Similarly, WK&#x02010;MAP1 induced substantial cytotoxicity in RAW cells, with only about 10% viability at 100&#x02009;&#x003bc;M. Cytotoxicity decreased with concentration, showing approximately 50% cell viability at 25&#x02009;&#x003bc;M and 90% at 12.5&#x02009;&#x003bc;M, mirroring the pattern observed in FN1 cells. This suggests a broad&#x02010;spectrum effect amenable to therapeutic modulation via dose adjustment.</p><p>In contrast, Suchi et&#x000a0;al.&#x000a0;(<xref rid="cbdd70130-bib-0047" ref-type="bibr">2023</xref>) observed a moderately higher cytotoxic effect on RAW cells using 36&#x02009;&#x003bc;M of the YS12 peptide from <styled-content style="fixed-case" toggle="no">
<italic toggle="no">Bacillus velezensis</italic>
</styled-content>, resulting in approximately 83% cell viability. These findings suggest that WG&#x02010;MAP2 is comparatively less cytotoxic to nontarget cells at equivalent or even higher concentrations. In addition, cytotoxicity assays with WG&#x02010;MAP2 showed approximately 90% and 50% viability in FN1 cells at concentrations of 6.25 and 25&#x02009;&#x003bc;M, respectively. This analogue peptide exhibited minimal cytotoxicity in RAW cells, maintaining around 90% viability even at the highest tested concentration of 100&#x02009;&#x003bc;M. Lay et&#x000a0;al.&#x000a0;(<xref rid="cbdd70130-bib-0027" ref-type="bibr">2019</xref>) described a peptide isolated from the <italic toggle="yes">Nicotiana occidentalis</italic> plant, which exhibited cytotoxic activity against human adult dermal fibroblasts at a concentration of approximately 10&#x02009;&#x003bc;M further emphasizing the relative safety of WG&#x02010;MAP2 under comparable experimental conditions.</p><p>In correlation, the in&#x000a0;vitro evaluation of WK&#x02010;MAP1 and WG&#x02010;MAP2 supports their distinct cytotoxic and hemolytic profiles. Although WK&#x02010;MAP1 displays potent and broad cytotoxicity, WG&#x02010;MAP2 exhibits selective action toward FN1 cells with low toxicity to RAW cells and erythrocytes. Comparative analysis with previously reported peptides underscores the advantageous profile of WG&#x02010;MAP2, suggesting its promise as a safer and more selective therapeutic candidate. Further studies involving mechanistic exploration and in&#x000a0;vivo models are warranted to confirm its potential clinical applications.</p><p>Molecular docking experiments provided valuable insights into the mechanisms underlying the action of these peptides. The analogue peptides showed greater affinity for mimetic membranes of gram&#x02010;negative bacteria, efficiently penetrating these membranes. In biological membranes, hydrogen bonding primarily involves the polar headgroups of phospholipids. Functional groups such as phosphate (<mml:math id="jats-math-5" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:mo>&#x02212;</mml:mo><mml:msubsup><mml:mi>PO</mml:mi><mml:mn>4</mml:mn><mml:mrow><mml:mn>3</mml:mn><mml:mo>&#x02212;</mml:mo></mml:mrow></mml:msubsup></mml:mrow></mml:mrow></mml:math>) and hydroxyl (&#x02013;OH), prevalent in phosphatidylethanolamine, phosphatidylglycerol, and cardiolipin. The main phospholipids in bacterial membranes act as key hydrogen bond donors and acceptors (Epand et&#x000a0;al.&#x000a0;<xref rid="cbdd70130-bib-0011" ref-type="bibr">2016</xref>; Zhang and Rock&#x000a0;<xref rid="cbdd70130-bib-0059" ref-type="bibr">2008</xref>). These polar functional groups interact with peptide residues bearing amid, hydroxyl, or charged side chains, facilitating membrane recognition. Conversely, aliphatic residues like leucine, isoleucine, and valine are nonpolar and do not participate in conventional hydrogen bonding (White and Wimley&#x000a0;<xref rid="cbdd70130-bib-0052" ref-type="bibr">1999</xref>). Their primary role is hydrophobic interaction with the lipid acyl chains, contributing to membrane insertion and disruption, being the key features of AMP activity (Brogden&#x000a0;<xref rid="cbdd70130-bib-0005" ref-type="bibr">2005</xref>). Regarding gram&#x02010;positive models, we agree that their inclusion would offer valuable insight, given differences such as a thicker peptidoglycan layer and absence of an outer membrane (Silhavy et&#x000a0;al.&#x000a0;<xref rid="cbdd70130-bib-0044" ref-type="bibr">2010</xref>; Brown et&#x000a0;al.&#x000a0;<xref rid="cbdd70130-bib-0006" ref-type="bibr">2013</xref>). However, our focus on Gram&#x02010;negative membranes was guided by stronger in&#x000a0;vitro activity against <styled-content style="fixed-case" toggle="no">
<italic toggle="no">K. pneumoniae</italic>
</styled-content> and corresponding in silico docking results showing higher interaction stability. Future studies will explore Gram&#x02010;positive systems to broaden our understanding of AMP selectivity. This observation aligns with previous findings that associate positive charge and amphipathic structure with the ability of AMPs to destabilize bacterial membranes (Hetta et&#x000a0;al.&#x000a0;<xref rid="cbdd70130-bib-0021" ref-type="bibr">2024</xref>; Uchikoga et&#x000a0;al.&#x000a0;<xref rid="cbdd70130-bib-0049" ref-type="bibr">2013</xref>).</p><p>Although AMPs present a promising alternative for the treatment of infectious diseases, their susceptibility to proteolytic degradation remains a significant limitation during their development (Louren&#x000e7;o et&#x000a0;al.&#x000a0;<xref rid="cbdd70130-bib-0029" ref-type="bibr">2023</xref>). Given these challenges, there has been an increasing focus on exploring strategies to enhance the stability and delivery of AMPs, particularly through the use of nanostructures, to overcome potential limitations (Wang et&#x000a0;al.&#x000a0;<xref rid="cbdd70130-bib-0051" ref-type="bibr">2021</xref>). AMPs offer a compelling alternative to conventional antibiotics in combating bacterial infections, as they tend to have a lower propensity to promote antimicrobial resistance compared to widely used antibiotics in clinical settings (Xuan et&#x000a0;al.&#x000a0;<xref rid="cbdd70130-bib-0055" ref-type="bibr">2023</xref>). Furthermore, the validation of in&#x000a0;vivo models is a critical component of drug development, as it enables the assessment of a complex biological system in relevant species, providing valuable insights into the pharmacokinetics, efficacy, and safety profiles of potential therapies (Pandey and Dvorakova&#x000a0;<xref rid="cbdd70130-bib-0039" ref-type="bibr">2019</xref>). Addressing the broader&#x02010;spectrum antimicrobial efficacy, stability, and delivery challenges of AMPs in such models is essential for advancing their therapeutic potential.</p><p>Although these results are promising, future research should explore the in&#x000a0;vivo efficacy of these peptides and optimize their pharmacokinetic and pharmacodynamic properties. Overall, this study demonstrates the efficacy and safety of WK&#x02010;MAP1 and WG&#x02010;MAP2, solidifying their potential as candidates for innovative antimicrobial therapies. The rational design strategy employed, combined with comprehensive experimental evaluations, represents a significant advancement in the development of AMPs as a solution to bacterial resistance.</p></sec><sec sec-type="conclusions" id="cbdd70130-sec-0021"><label>5</label><title>Conclusions</title><p>The findings of this study indicate that the peptides WK&#x02010;MAP1 and WG&#x02010;MAP2 hold promising potential as candidates for the development of novel antimicrobial therapies. These peptides demonstrated significant efficacy against MDR <styled-content style="fixed-case" toggle="no">
<italic toggle="no">K. pneumoniae</italic>
</styled-content> strains, with amphipathic properties and &#x003b1;&#x02010;helical conformations essential for efficient interaction with bacterial membranes. Furthermore, their ability to inhibit biofilm formation underscores their relevance as potential therapeutic tools in preventing device&#x02010;associated infections, which remain a major challenge in the clinical management of resistant pathogens.</p><p>To build on the progress achieved, further studies are required to evaluate their efficacy in in&#x000a0;vivo models and to investigate their pharmacokinetic and pharmacodynamic properties. These steps are indispensable to translate the preliminary findings of this study into practical and safe clinical applications.</p><p>Further studies involving mechanistic exploration and in&#x000a0;vivo models are warranted to confirm its potential clinical applications. In summary, this study represents a significant contribution to the development of AMPs as viable alternatives to address bacterial resistance, providing a solid foundation for future research and therapeutic innovations.</p></sec><sec sec-type="COI-statement" id="cbdd70130-sec-0022"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest.</p></sec><sec sec-type="supplementary-material"><title>Supporting information</title><supplementary-material id="cbdd70130-supitem-0001" position="float" content-type="local-data"><caption><p>
Figure S1
</p></caption><media xlink:href="CBDD-105-e70130-s001.docx"/></supplementary-material><supplementary-material id="cbdd70130-supitem-0002" position="float" content-type="local-data"><caption><p>
Table&#x000a0;S1
</p></caption><media xlink:href="CBDD-105-e70130-s002.docx"/></supplementary-material></sec></body><back><ack id="cbdd70130-sec-25"><title>Acknowledgements</title><p>The Article Processing Charge for the publication of this research was funded by the Coordena&#x000e7;&#x000e3;o de Aperfei&#x000e7;oamento de Pessoal de N&#x000ed;vel Superior &#x02010; Brasil (CAPES) (ROR identifier: 00x0ma614).</p></ack><sec sec-type="data-availability" id="cbdd70130-sec-0024"><title>Data Availability Statement</title><p>The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions.</p></sec><ref-list content-type="cited-references" id="cbdd70130-bibl-0001"><title>References</title><ref id="cbdd70130-bib-0001"><mixed-citation publication-type="journal" id="cbdd70130-cit-0001">
<string-name>
<surname>Adasme</surname>, <given-names>M. F.</given-names>
</string-name>, <string-name>
<given-names>K. L.</given-names>
<surname>Linnemann</surname>
</string-name>, <string-name>
<given-names>S. N.</given-names>
<surname>Bolz</surname>
</string-name>, et&#x000a0;al. <year>2021</year>. &#x0201c;<article-title>PLIP 2021: Expanding the Scope of the Protein&#x02013;Ligand Interaction Profiler to DNA and RNA</article-title>.&#x0201d; <source>Nucleic Acids Research</source>
<volume>49</volume>: <fpage>W530</fpage>&#x02013;<lpage>W534</lpage>.<pub-id pub-id-type="pmid">33950214</pub-id>
</mixed-citation></ref><ref id="cbdd70130-bib-0002"><mixed-citation publication-type="journal" id="cbdd70130-cit-0002">
<string-name>
<surname>Alreshidi</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<given-names>R.</given-names>
<surname>Badraoui</surname>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Adnan</surname>
</string-name>, et&#x000a0;al. <year>2023</year>. &#x0201c;<article-title>Phytochemical Profiling, Antibacterial, and Antibiofilm Activities of <italic toggle="yes">Sargassum</italic> sp. (Brown Algae) From the Red Sea: ADMET Prediction and Molecular Docking Analysis</article-title>.&#x0201d; <source>Algal Research</source>
<volume>69</volume>: <elocation-id>102912</elocation-id>.</mixed-citation></ref><ref id="cbdd70130-bib-0003"><mixed-citation publication-type="journal" id="cbdd70130-cit-0003">
<string-name>
<surname>Ashwath</surname>, <given-names>P.</given-names>
</string-name>, <string-name>
<given-names>V. K.</given-names>
<surname>Deekshit</surname>
</string-name>, <string-name>
<given-names>A.</given-names>
<surname>Rohit</surname>
</string-name>, et&#x000a0;al. <year>2022</year>. &#x0201c;<article-title>Biofilm Formation and Associated Gene Expression in Multidrug&#x02010;Resistant Klebsiella Pneumoniae Isolated From Clinical Specimens</article-title>.&#x0201d; <source>Current Microbiology</source>
<volume>79</volume>: <fpage>73</fpage>.<pub-id pub-id-type="pmid">35084583</pub-id>
</mixed-citation></ref><ref id="cbdd70130-bib-0004"><mixed-citation publication-type="journal" id="cbdd70130-cit-0004">
<string-name>
<surname>Barik</surname>, <given-names>S.</given-names>
</string-name>
<year>2020</year>. &#x0201c;<article-title>The Uniqueness of Tryptophan in Biology: Properties, Metabolism, Interactions and Localization in Proteins</article-title>.&#x0201d; <source>International Journal of Molecular Sciences</source>
<volume>21</volume>: <fpage>1</fpage>&#x02013;<lpage>22</lpage>.</mixed-citation></ref><ref id="cbdd70130-bib-1004"><mixed-citation publication-type="journal" id="cbdd70130-cit-1004">
<string-name>
<surname>Batoni</surname>, <given-names>G.</given-names>
</string-name>, <string-name>
<given-names>G.</given-names>
<surname>Maisetta</surname>
</string-name>, and <string-name>
<given-names>S.</given-names>
<surname>Esin</surname>
</string-name>. <year>2016</year>. &#x0201c;<article-title>Antimicrobial Peptides and Their Interaction with Biofilms of Medically Relevant Bacteria</article-title>.&#x0201d; <source>Biochimica et Biophysica Acta (BBA) &#x02010; Biomembranes</source>
<volume>1858</volume>, no. <issue>5</issue>: <fpage>1044</fpage>&#x02013;<lpage>1060</lpage>.<pub-id pub-id-type="pmid">26525663</pub-id>
</mixed-citation></ref><ref id="cbdd70130-bib-0005"><mixed-citation publication-type="journal" id="cbdd70130-cit-0005">
<string-name>
<surname>Brogden</surname>, <given-names>K. A.</given-names>
</string-name>
<year>2005</year>. &#x0201c;<article-title>Antimicrobial Peptides: Pore Formers or Metabolic Inhibitors in Bacteria?</article-title>&#x0201d; <source>Nature Reviews. Microbiology</source>
<volume>3</volume>: <fpage>238</fpage>&#x02013;<lpage>250</lpage>.<pub-id pub-id-type="pmid">15703760</pub-id>
</mixed-citation></ref><ref id="cbdd70130-bib-0006"><mixed-citation publication-type="journal" id="cbdd70130-cit-0006">
<string-name>
<surname>Brown</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<given-names>J. P.</given-names>
<surname>Santa Maria</surname>
</string-name>, and <string-name>
<given-names>S.</given-names>
<surname>Walker</surname>
</string-name>. <year>2013</year>. &#x0201c;<article-title>Wall Teichoic Acids of Gram&#x02010;Positive Bacteria</article-title>.&#x0201d; <source>Annual Review of Microbiology</source>
<volume>67</volume>, no. <issue>1</issue>: <fpage>313</fpage>.</mixed-citation></ref><ref id="cbdd70130-bib-1002"><mixed-citation publication-type="journal" id="cbdd70130-cit-1002">
<string-name>
<surname>Buccini</surname>, <given-names>D. F.</given-names>
</string-name>, <string-name>
<given-names>M. I. L.</given-names>
<surname>Esteves</surname>
</string-name>, <string-name>
<given-names>E. G. L.</given-names>
<surname>Alves</surname>
</string-name>, et&#x000a0;al. <year>2018</year>. &#x0201c;<article-title>Anti&#x02010;Inflammatory and Antinociceptive Activities of <italic toggle="yes">Rhipicephalus microplus</italic> Saliva</article-title>.&#x0201d; <source>Asian Pacific Journal of Tropical Biomedicine</source>
<volume>8</volume>, no. <issue>4</issue>: <fpage>194</fpage>&#x02013;<lpage>200</lpage>.</mixed-citation></ref><ref id="cbdd70130-bib-0007"><mixed-citation publication-type="journal" id="cbdd70130-cit-0007">
<string-name>
<surname>Chan</surname>, <given-names>D. I.</given-names>
</string-name>, <string-name>
<given-names>E. J.</given-names>
<surname>Prenner</surname>
</string-name>, and <string-name>
<given-names>H. J.</given-names>
<surname>Vogel</surname>
</string-name>. <year>2006</year>. &#x0201c;<article-title>Tryptophan&#x02010; and Arginine&#x02010;Rich Antimicrobial Peptides: Structures and Mechanisms of Action</article-title>.&#x0201d; <source>Biochimica et Biophysica Acta &#x02010; Biomembranes</source>
<volume>1758</volume>: <fpage>1184</fpage>.</mixed-citation></ref><ref id="cbdd70130-bib-0008"><mixed-citation publication-type="journal" id="cbdd70130-cit-0008">
<string-name>
<surname>De Oliveira</surname>, <given-names>D. M. P.</given-names>
</string-name>, <string-name>
<given-names>B. M.</given-names>
<surname>Forde</surname>
</string-name>, <string-name>
<given-names>T. J.</given-names>
<surname>Kidd</surname>
</string-name>, et&#x000a0;al. <year>2020</year>. &#x0201c;<article-title>Antimicrobial Resistance in ESKAPE Pathogens</article-title>.&#x0201d; <source>Clinical Microbiology Reviews</source>
<volume>33</volume>: <elocation-id>e00181&#x02010;19</elocation-id>. <pub-id pub-id-type="doi">10.1128/cmr.00181</pub-id>.<pub-id pub-id-type="pmid">32404435</pub-id>
</mixed-citation></ref><ref id="cbdd70130-bib-0009"><mixed-citation publication-type="journal" id="cbdd70130-cit-0009">
<string-name>
<surname>Ding</surname>, <given-names>D.</given-names>
</string-name>, <string-name>
<given-names>B.</given-names>
<surname>Wang</surname>
</string-name>, <string-name>
<given-names>X.</given-names>
<surname>Zhang</surname>
</string-name>, et&#x000a0;al. <year>2023</year>. &#x0201c;<article-title>The Spread of Antibiotic Resistance to Humans and Potential Protection Strategies</article-title>.&#x0201d; <source>Ecotoxicology and Environmental Safety</source>
<volume>254</volume>: <elocation-id>114734</elocation-id>.<pub-id pub-id-type="pmid">36950985</pub-id>
</mixed-citation></ref><ref id="cbdd70130-bib-0010"><mixed-citation publication-type="journal" id="cbdd70130-cit-0010">
<string-name>
<surname>Drenth</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<given-names>J. N.</given-names>
<surname>Jansonius</surname>
</string-name>, <string-name>
<given-names>R.</given-names>
<surname>Koekoek</surname>
</string-name>, <string-name>
<given-names>H. M.</given-names>
<surname>Swen</surname>
</string-name>, and <string-name>
<given-names>B. G.</given-names>
<surname>Wolthers</surname>
</string-name>. <year>1968</year>. &#x0201c;<article-title>Structure of Papain</article-title>.&#x0201d; <source>Nature</source>
<volume>218</volume>: <fpage>929</fpage>&#x02013;<lpage>932</lpage>.<pub-id pub-id-type="pmid">5681232</pub-id>
</mixed-citation></ref><ref id="cbdd70130-bib-0011"><mixed-citation publication-type="journal" id="cbdd70130-cit-0011">
<string-name>
<surname>Epand</surname>, <given-names>R. M.</given-names>
</string-name>, <string-name>
<given-names>C.</given-names>
<surname>Walker</surname>
</string-name>, <string-name>
<given-names>R. F.</given-names>
<surname>Epand</surname>
</string-name>, and <string-name>
<given-names>N. A.</given-names>
<surname>Magarvey</surname>
</string-name>. <year>2016</year>. &#x0201c;<article-title>Molecular Mechanisms of Membrane Targeting Antibiotics</article-title>.&#x0201d; <source>Biochimica et Biophysica Acta &#x02010; Biomembranes</source>
<volume>1858</volume>, no. <issue>5</issue>: <fpage>980</fpage>.</mixed-citation></ref><ref id="cbdd70130-bib-1005"><mixed-citation publication-type="journal" id="cbdd70130-cit-1005">
<string-name>
<surname>Erriah</surname>, <given-names>P.</given-names>
</string-name>, <string-name>
<given-names>S. L.</given-names>
<surname>Puan</surname>
</string-name>, <string-name>
<given-names>N. M.</given-names>
<surname>Yahaya</surname>
</string-name>, et&#x000a0;al. <year>2024</year>. &#x0201c;<article-title>Harnessing Bacterial Antimicrobial Peptides: A Comprehensive Review on Properties, Mechanisms, Applications, and Challenges in Combating Antimicrobial Resistance</article-title>.&#x0201d; <source>Journal of Applied Microbiology</source>: <elocation-id>lxae290</elocation-id>, ahead of print.<pub-id pub-id-type="pmid">39558882</pub-id>
</mixed-citation></ref><ref id="cbdd70130-bib-0012"><mixed-citation publication-type="journal" id="cbdd70130-cit-0012">
<string-name>
<surname>Erriah</surname>, <given-names>P.</given-names>
</string-name>, <string-name>
<given-names>S. L.</given-names>
<surname>Puan</surname>
</string-name>, <string-name>
<given-names>N. M.</given-names>
<surname>Yahaya</surname>
</string-name>, et&#x000a0;al. <year>2025</year>. &#x0201c;<article-title>Harnessing Bacterial Antimicrobial Peptides: A Comprehensive Review on Properties, Mechanisms, Applications, and Challenges in Combating Antimicrobial Resistance</article-title>.&#x0201d; <source>Journal of Applied Microbiology</source>
<volume>136</volume>: <elocation-id>lxae290</elocation-id>.<pub-id pub-id-type="pmid">40036746</pub-id>
</mixed-citation></ref><ref id="cbdd70130-bib-0013"><mixed-citation publication-type="journal" id="cbdd70130-cit-0013">
<string-name>
<surname>Falcigno</surname>, <given-names>L.</given-names>
</string-name>, <string-name>
<given-names>G.</given-names>
<surname>D'auria</surname>
</string-name>, <string-name>
<given-names>G.</given-names>
<surname>Palmieri</surname>
</string-name>, et&#x000a0;al. <year>2021</year>. &#x0201c;<article-title>Key Physicochemical Determinants in the Antimicrobial Peptide RiLK1 Promote Amphipathic Structures</article-title>.&#x0201d; <source>International Journal of Molecular Sciences</source>
<volume>22</volume>: <elocation-id>10011</elocation-id>.<pub-id pub-id-type="pmid">34576174</pub-id>
</mixed-citation></ref><ref id="cbdd70130-bib-0014"><mixed-citation publication-type="journal" id="cbdd70130-cit-0014">
<string-name>
<surname>Feng</surname>, <given-names>X.</given-names>
</string-name>, <string-name>
<given-names>S.</given-names>
<surname>Jin</surname>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Wang</surname>
</string-name>, et&#x000a0;al. <year>2020</year>. &#x0201c;<article-title>The Critical Role of Tryptophan in the Antimicrobial Activity and Cell Toxicity of the Duck Antimicrobial Peptide DCATH</article-title>.&#x0201d; <source>Frontiers in Microbiology</source>
<volume>11</volume>: <elocation-id>1146</elocation-id>.<pub-id pub-id-type="pmid">32670215</pub-id>
</mixed-citation></ref><ref id="cbdd70130-bib-0016"><mixed-citation publication-type="book" id="cbdd70130-cit-0016">
<string-name>
<surname>Gaur</surname>, <given-names>G.</given-names>
</string-name>, <string-name>
<given-names>U. L.</given-names>
<surname>Raj</surname>
</string-name>, <string-name>
<given-names>S.</given-names>
<surname>Dang</surname>
</string-name>, <string-name>
<given-names>S.</given-names>
<surname>Gupta</surname>
</string-name>, and <string-name>
<given-names>R.</given-names>
<surname>Gabrani</surname>
</string-name>. <year>2018</year>. &#x0201c;<part-title>Plant&#x02010;Derived Drug Molecules as Antibacterial Agents</part-title>.&#x0201d; In <source>Functional Food and Human Health</source>, edited by <person-group person-group-type="editor">
<string-name>
<given-names>V.</given-names>
<surname>Rani</surname>
</string-name>
</person-group> and <person-group person-group-type="editor">
<string-name>
<given-names>U. C. S.</given-names>
<surname>Yadav</surname>
</string-name>
</person-group>, <fpage>143</fpage>&#x02013;<lpage>171</lpage>. <publisher-name>Springer Singapore</publisher-name>.</mixed-citation></ref><ref id="cbdd70130-bib-0017"><mixed-citation publication-type="journal" id="cbdd70130-cit-0017">
<string-name>
<surname>Giuliani</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<given-names>G.</given-names>
<surname>Pirri</surname>
</string-name>, and <string-name>
<given-names>S.</given-names>
<surname>Nicoletto</surname>
</string-name>. <year>2007</year>. &#x0201c;<article-title>Antimicrobial Peptides: An Overview of a Promising Class of Therapeutics</article-title>.&#x0201d; <source>Open Life Sciences</source>
<volume>2</volume>, no. <issue>1</issue>: <fpage>1</fpage>&#x02013;<lpage>33</lpage>.</mixed-citation></ref><ref id="cbdd70130-bib-0018"><mixed-citation publication-type="journal" id="cbdd70130-cit-0018">
<string-name>
<surname>Greenfield</surname>, <given-names>N. J.</given-names>
</string-name>
<year>2006</year>. &#x0201c;<article-title>Using Circular Dichroism Spectra to Estimate Protein Secondary Structure</article-title>.&#x0201d; <source>Nature Protocols</source>
<volume>1</volume>: <fpage>2876</fpage>&#x02013;<lpage>2890</lpage>.<pub-id pub-id-type="pmid">17406547</pub-id>
</mixed-citation></ref><ref id="cbdd70130-bib-0019"><mixed-citation publication-type="journal" id="cbdd70130-cit-0019">
<string-name>
<surname>Hall</surname>, <given-names>C. W.</given-names>
</string-name>, and <string-name>
<given-names>T.&#x02010;F.</given-names>
<surname>Mah</surname>
</string-name>. <year>2017</year>. &#x0201c;<article-title>Molecular Mechanisms of Biofilm&#x02010;Based Antibiotic Resistance and Tolerance in Pathogenic Bacteria</article-title>.&#x0201d; <source>FEMS Microbiology Reviews</source>
<volume>41</volume>: <fpage>276</fpage>&#x02013;<lpage>301</lpage>.<pub-id pub-id-type="pmid">28369412</pub-id>
</mixed-citation></ref><ref id="cbdd70130-bib-0020"><mixed-citation publication-type="journal" id="cbdd70130-cit-0020">
<string-name>
<surname>Hennequin</surname>, <given-names>C.</given-names>
</string-name>, and <string-name>
<given-names>F.</given-names>
<surname>Robin</surname>
</string-name>. <year>2016</year>. &#x0201c;<article-title>Correlation Between Antimicrobial Resistance and Virulence in Klebsiella Pneumoniae</article-title>.&#x0201d; <source>European Journal of Clinical Microbiology &#x00026; Infectious Diseases</source>
<volume>35</volume>: <fpage>333</fpage>&#x02013;<lpage>341</lpage>.<pub-id pub-id-type="pmid">26718943</pub-id>
</mixed-citation></ref><ref id="cbdd70130-bib-0021"><mixed-citation publication-type="journal" id="cbdd70130-cit-0021">
<string-name>
<surname>Hetta</surname>, <given-names>H. F.</given-names>
</string-name>, <string-name>
<given-names>N.</given-names>
<surname>Sirag</surname>
</string-name>, <string-name>
<given-names>S. M.</given-names>
<surname>Alsharif</surname>
</string-name>, et&#x000a0;al. <year>2024</year>. &#x0201c;<article-title>Antimicrobial Peptides: The Game&#x02010;Changer in the Epic Battle Against Multidrug&#x02010;Resistant Bacteria</article-title>.&#x0201d; <source>Pharmaceuticals</source>
<volume>17</volume>: <elocation-id>1555</elocation-id>.<pub-id pub-id-type="pmid">39598464</pub-id>
</mixed-citation></ref><ref id="cbdd70130-bib-0022"><mixed-citation publication-type="journal" id="cbdd70130-cit-0022">
<string-name>
<surname>Huang</surname>, <given-names>Y.</given-names>
</string-name>, <string-name>
<given-names>J.</given-names>
<surname>Huang</surname>
</string-name>, and <string-name>
<given-names>Y.</given-names>
<surname>Chen</surname>
</string-name>. <year>2010</year>. &#x0201c;<article-title>Alpha&#x02010;Helical Cationic Antimicrobial Peptides: Relationships of Structure and Function</article-title>.&#x0201d; <source>Protein &#x00026; Cell</source>
<volume>1</volume>: <fpage>143</fpage>&#x02013;<lpage>152</lpage>.<pub-id pub-id-type="pmid">21203984</pub-id>
</mixed-citation></ref><ref id="cbdd70130-bib-1008"><mixed-citation publication-type="journal" id="cbdd70130-cit-1008">
<string-name>
<surname>Juntavee</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<given-names>J.</given-names>
<surname>Peerapattana</surname>
</string-name>, <string-name>
<given-names>A.</given-names>
<surname>Ratanathongkam</surname>
</string-name>, <string-name>
<given-names>N.</given-names>
<surname>Nualkaew</surname>
</string-name>, <string-name>
<given-names>S.</given-names>
<surname>Chatchiwiwattana</surname>
</string-name>, and <string-name>
<given-names>P.</given-names>
<surname>Treesuwan</surname>
</string-name>. <year>2014</year>. &#x0201c;<article-title>The Antibacterial Effects of Apacaries Gel on <italic toggle="yes">Streptococcus mutans</italic>: An In&#x000a0;Vitro Study</article-title>.&#x0201d; <source>International Journal of Clinical Pediatric Dentistry</source>
<volume>7</volume>, no. <issue>2</issue>: <fpage>77</fpage>&#x02013;<lpage>81</lpage>.<pub-id pub-id-type="pmid">25356004</pub-id>
</mixed-citation></ref><ref id="cbdd70130-bib-0023"><mixed-citation publication-type="journal" id="cbdd70130-cit-0023">
<string-name>
<surname>Kamphuis</surname>, <given-names>I. G.</given-names>
</string-name>, <string-name>
<given-names>K. H.</given-names>
<surname>Kalk</surname>
</string-name>, <string-name>
<given-names>M. B. A.</given-names>
<surname>Swarte</surname>
</string-name>, and <string-name>
<given-names>J.</given-names>
<surname>Drenth</surname>
</string-name>. <year>1984</year>. &#x0201c;<article-title>Structure of Papain Refined at 1.65 &#x000c5; Resolution</article-title>.&#x0201d; <source>Journal of Molecular Biology</source>
<volume>179</volume>: <fpage>233</fpage>&#x02013;<lpage>256</lpage>.<pub-id pub-id-type="pmid">6502713</pub-id>
</mixed-citation></ref><ref id="cbdd70130-bib-0024"><mixed-citation publication-type="journal" id="cbdd70130-cit-0024">
<string-name>
<surname>Kelly</surname>, <given-names>S. M.</given-names>
</string-name>, and <string-name>
<given-names>N. C.</given-names>
<surname>Price</surname>
</string-name>. <year>2006</year>. &#x0201c;<article-title>Circular Dichroism to Study Protein Interactions</article-title>.&#x0201d; <source>Current Protocols in Protein Science</source>
<volume>46</volume>: <fpage>20.10.1</fpage>.</mixed-citation></ref><ref id="cbdd70130-bib-0025"><mixed-citation publication-type="journal" id="cbdd70130-cit-0025">
<string-name>
<surname>Kim</surname>, <given-names>Y.&#x02010;M.</given-names>
</string-name>, <string-name>
<given-names>S.&#x02010;C.</given-names>
<surname>Park</surname>
</string-name>, <string-name>
<given-names>Y.</given-names>
<surname>Yoon</surname>
</string-name>, <string-name>
<given-names>M.&#x02010;K.</given-names>
<surname>Jang</surname>
</string-name>, and <string-name>
<given-names>J. R.</given-names>
<surname>Lee</surname>
</string-name>. <year>2024</year>. &#x0201c;<article-title>Effect of Tryptophan Position and Lysine/Arginine Substitution in Antimicrobial Peptides on Antifungal Action</article-title>.&#x0201d; <source>Biochemical and Biophysical Research Communications</source>
<volume>704</volume>: <elocation-id>149700</elocation-id>.<pub-id pub-id-type="pmid">38401304</pub-id>
</mixed-citation></ref><ref id="cbdd70130-bib-0026"><mixed-citation publication-type="journal" id="cbdd70130-cit-0026">
<string-name>
<surname>Klousnitzer</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<given-names>W.</given-names>
<surname>Xiang</surname>
</string-name>, <string-name>
<given-names>V. M.</given-names>
<surname>Polynice</surname>
</string-name>, and <string-name>
<given-names>B.</given-names>
<surname>Deslouches</surname>
</string-name>. <year>2024</year>. &#x0201c;<article-title>Comparative Properties of Helical and Linear Amphipathicity of Peptides Composed of Arginine, Tryptophan, and Valine</article-title>.&#x0201d; <source>Antibiotics</source>
<volume>13</volume>: <elocation-id>954</elocation-id>.<pub-id pub-id-type="pmid">39452220</pub-id>
</mixed-citation></ref><ref id="cbdd70130-bib-0027"><mixed-citation publication-type="journal" id="cbdd70130-cit-0027">
<string-name>
<surname>Lay</surname>, <given-names>F. T.</given-names>
</string-name>, <string-name>
<given-names>G. F.</given-names>
<surname>Ryan</surname>
</string-name>, <string-name>
<given-names>S.</given-names>
<surname>Caria</surname>
</string-name>, et&#x000a0;al. <year>2019</year>. &#x0201c;<article-title>Structural and Functional Characterization of the Membrane&#x02010;Permeabilizing Activity of <italic toggle="yes">Nicotiana occidentalis</italic> Defensin NoD173 and Protein Engineering to Enhance Oncolysis</article-title>.&#x0201d; <source>FASEB Journal</source>
<volume>33</volume>: <fpage>6470</fpage>&#x02013;<lpage>6482</lpage>.<pub-id pub-id-type="pmid">30794440</pub-id>
</mixed-citation></ref><ref id="cbdd70130-bib-0028"><mixed-citation publication-type="journal" id="cbdd70130-cit-0028">
<string-name>
<surname>Li</surname>, <given-names>Y.</given-names>
</string-name>, and <string-name>
<given-names>M.</given-names>
<surname>Ni</surname>
</string-name>. <year>2023</year>. &#x0201c;<article-title>Regulation of Biofilm Formation in <italic toggle="yes">Klebsiella pneumoniae</italic>
</article-title>.&#x0201d; <source>Frontiers in Microbiology</source>
<volume>14</volume>: <elocation-id>1238482</elocation-id>.<pub-id pub-id-type="pmid">37744914</pub-id>
</mixed-citation></ref><ref id="cbdd70130-bib-0029"><mixed-citation publication-type="journal" id="cbdd70130-cit-0029">
<string-name>
<surname>Louren&#x000e7;o</surname>, <given-names>A. L. P.</given-names>
</string-name>, <string-name>
<given-names>T. B.</given-names>
<surname>Rios</surname>
</string-name>, <string-name>
<given-names>&#x000c1;. P.</given-names>
<surname>da Silva</surname>
</string-name>, <string-name>
<given-names>O. L.</given-names>
<surname>Franco</surname>
</string-name>, and <string-name>
<given-names>M. H. S.</given-names>
<surname>Ramada</surname>
</string-name>. <year>2023</year>. &#x0201c;<article-title>Peptide Stapling Applied to Antimicrobial Peptides</article-title>.&#x0201d; <source>Antibiotics</source>
<volume>12</volume>: <elocation-id>1400</elocation-id>.<pub-id pub-id-type="pmid">37760697</pub-id>
</mixed-citation></ref><ref id="cbdd70130-bib-0030"><mixed-citation publication-type="journal" id="cbdd70130-cit-0030">
<string-name>
<surname>Mahlapuu</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<given-names>J.</given-names>
<surname>H&#x000e5;kansson</surname>
</string-name>, <string-name>
<given-names>L.</given-names>
<surname>Ringstad</surname>
</string-name>, and <string-name>
<given-names>C.</given-names>
<surname>Bj&#x000f6;rn</surname>
</string-name>. <year>2016</year>. &#x0201c;<article-title>Antimicrobial Peptides: An Emerging Category of Therapeutic Agents</article-title>.&#x0201d; <source>Frontiers in Cellular and Infection Microbiology</source>
<volume>6</volume>: <elocation-id>194</elocation-id>.<pub-id pub-id-type="pmid">28083516</pub-id>
</mixed-citation></ref><ref id="cbdd70130-bib-0031"><mixed-citation publication-type="journal" id="cbdd70130-cit-0031">
<string-name>
<surname>Martinez</surname>, <given-names>M. M. B.</given-names>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Corleto</surname>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Weschenfeller</surname>
</string-name>, et&#x000a0;al. <year>2025</year>. &#x0201c;<article-title>In Vitro and In&#x000a0;Vivo Evaluation of the De Novo Designed Antimicrobial Peptide P6.2 Against a KPC&#x02010;Producing <italic toggle="yes">P. aeruginosa</italic> Clinical Isolate</article-title>.&#x0201d; <source>Biomolecules</source>
<volume>15</volume>: <elocation-id>339</elocation-id>.<pub-id pub-id-type="pmid">40149875</pub-id>
</mixed-citation></ref><ref id="cbdd70130-bib-0032"><mixed-citation publication-type="journal" id="cbdd70130-cit-0032">
<string-name>
<surname>Matali&#x00144;ska</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<given-names>P. F. J.</given-names>
<surname>Lipi&#x00144;ski</surname>
</string-name>, <string-name>
<given-names>P.</given-names>
<surname>Kosson</surname>
</string-name>, <string-name>
<given-names>K.</given-names>
<surname>Kosi&#x00144;ska</surname>
</string-name>, and <string-name>
<given-names>A.</given-names>
<surname>Misicka</surname>
</string-name>. <year>2020</year>. &#x0201c;<article-title>In Vivo, In&#x000a0;Vitro and In Silico Studies of the Hybrid Compound AA3266, An Opioid Agonist/NK1R Antagonist With Selective Cytotoxicity</article-title>.&#x0201d; <source>International Journal of Molecular Sciences</source>
<volume>21</volume>, no. <issue>20</issue>: <elocation-id>7738</elocation-id>.<pub-id pub-id-type="pmid">33086743</pub-id>
</mixed-citation></ref><ref id="cbdd70130-bib-0033"><mixed-citation publication-type="journal" id="cbdd70130-cit-0033">
<string-name>
<surname>Mishra</surname>, <given-names>A. K.</given-names>
</string-name>, <string-name>
<given-names>J.</given-names>
<surname>Choi</surname>
</string-name>, <string-name>
<given-names>E.</given-names>
<surname>Moon</surname>
</string-name>, and <string-name>
<given-names>K. H.</given-names>
<surname>Baek</surname>
</string-name>. <year>2018</year>. &#x0201c;<article-title>Tryptophan&#x02010;Rich and Proline&#x02010;Rich Antimicrobial Peptides</article-title>.&#x0201d; <source>Molecules</source>
<volume>23</volume>: <fpage>815</fpage>.<pub-id pub-id-type="pmid">29614844</pub-id>
</mixed-citation></ref><ref id="cbdd70130-bib-0034"><mixed-citation publication-type="journal" id="cbdd70130-cit-0034">
<string-name>
<surname>Mosmann</surname>, <given-names>T.</given-names>
</string-name>
<year>1983</year>. &#x0201c;<article-title>Rapid Colorimetric Assay for Cellular Growth and Survival: Application to Proliferation and Cytotoxicity Assays</article-title>.&#x0201d; <source>Journal of Immunological Methods</source>
<volume>65</volume>: <fpage>55</fpage>&#x02013;<lpage>63</lpage>.<pub-id pub-id-type="pmid">6606682</pub-id>
</mixed-citation></ref><ref id="cbdd70130-bib-0035"><mixed-citation publication-type="journal" id="cbdd70130-cit-0035">
<string-name>
<surname>Mota</surname>, <given-names>V. D. S.</given-names>
</string-name>, <string-name>
<given-names>R. N. T.</given-names>
<surname>Turrini</surname>
</string-name>, and <string-name>
<given-names>V. D. B.</given-names>
<surname>Poveda</surname>
</string-name>. <year>2015</year>. &#x0201c;<article-title>Antimicrobial Activity of Eucalyptus Globulus Oil, Xylitol and Papain: A Pilot Study</article-title>.&#x0201d; <source>Revista da Escola de Enfermagem da USP</source>
<volume>49</volume>: <fpage>216</fpage>&#x02013;<lpage>220</lpage>.</mixed-citation></ref><ref id="cbdd70130-bib-0036"><mixed-citation publication-type="journal" id="cbdd70130-cit-0036">
<string-name>
<surname>O'Boyle</surname>, <given-names>N. M.</given-names>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Banck</surname>
</string-name>, <string-name>
<given-names>C. A.</given-names>
<surname>James</surname>
</string-name>, <string-name>
<given-names>C.</given-names>
<surname>Morley</surname>
</string-name>, <string-name>
<given-names>T.</given-names>
<surname>Vandermeersch</surname>
</string-name>, and <string-name>
<given-names>G. R.</given-names>
<surname>Hutchison</surname>
</string-name>. <year>2011</year>. &#x0201c;<article-title>Open Babel: An Open Chemical Toolbox</article-title>.&#x0201d; <source>Journal of Cheminformatics</source>
<volume>3</volume>: <fpage>33</fpage>.<pub-id pub-id-type="pmid">21982300</pub-id>
</mixed-citation></ref><ref id="cbdd70130-bib-0037"><mixed-citation publication-type="journal" id="cbdd70130-cit-0037">
<string-name>
<surname>Othman</surname>, <given-names>I. M. M.</given-names>
</string-name>, <string-name>
<given-names>M. A. M.</given-names>
<surname>Gad&#x02010;Elkareem</surname>
</string-name>, <string-name>
<given-names>H. A.</given-names>
<surname>Radwan</surname>
</string-name>, et&#x000a0;al. <year>2021</year>. &#x0201c;<article-title>Synthesis, Structure&#x02010;Activity Relationship and In Silico Studies of Novel Pyrazolothiazole and Thiazolopyridine Derivatives as Prospective Antimicrobial and Anticancer Agents</article-title>.&#x0201d; <source>ChemistrySelect</source>
<volume>6</volume>: <fpage>7860</fpage>&#x02013;<lpage>7872</lpage>.</mixed-citation></ref><ref id="cbdd70130-bib-0038"><mixed-citation publication-type="journal" id="cbdd70130-cit-0038">
<string-name>
<surname>Pag&#x000e8;s</surname>, <given-names>J.&#x02010;M.</given-names>
</string-name>, <string-name>
<given-names>C. E.</given-names>
<surname>James</surname>
</string-name>, and <string-name>
<given-names>M.</given-names>
<surname>Winterhalter</surname>
</string-name>. <year>2008</year>. &#x0201c;<article-title>The Porin and the Permeating Antibiotic: A Selective Diffusion Barrier in Gram&#x02010;Negative Bacteria</article-title>.&#x0201d; <source>Nature Reviews. Microbiology</source>
<volume>6</volume>: <fpage>893</fpage>&#x02013;<lpage>903</lpage>.<pub-id pub-id-type="pmid">18997824</pub-id>
</mixed-citation></ref><ref id="cbdd70130-bib-0039"><mixed-citation publication-type="journal" id="cbdd70130-cit-0039">
<string-name>
<surname>Pandey</surname>, <given-names>S.</given-names>
</string-name>, and <string-name>
<given-names>M. C.</given-names>
<surname>Dvorakova</surname>
</string-name>. <year>2019</year>. &#x0201c;<article-title>Endocrine, Metabolic &#x00026; Immune Disorders Drug Targets</article-title>.&#x0201d; <source>International Journal of Food Microbiology</source>
<volume>20</volume>: <fpage>25</fpage>.</mixed-citation></ref><ref id="cbdd70130-bib-0040"><mixed-citation publication-type="journal" id="cbdd70130-cit-0040">
<string-name>
<surname>Park</surname>, <given-names>Y.</given-names>
</string-name>, <string-name>
<given-names>H. N.</given-names>
<surname>Kim</surname>
</string-name>, <string-name>
<given-names>S. N.</given-names>
<surname>Park</surname>
</string-name>, et&#x000a0;al. <year>2004</year>. &#x0201c;<article-title>Design of Novel Analogues With Potent Antibiotic Activity Based on the Antimicrobial Peptide, HP(2&#x02010;9)&#x02010;ME(1&#x02010;12)</article-title>.&#x0201d; <source>Biotechnology Letters</source>
<volume>26</volume>: <fpage>493</fpage>&#x02013;<lpage>498</lpage>.<pub-id pub-id-type="pmid">15127790</pub-id>
</mixed-citation></ref><ref id="cbdd70130-bib-1001"><mixed-citation publication-type="journal" id="cbdd70130-cit-1001">
<string-name>
<surname>Rezende</surname>, <given-names>S. B.</given-names>
</string-name>, <string-name>
<given-names>L. P.</given-names>
<surname>Silva</surname>
</string-name>, <string-name>
<given-names>P. R. S.</given-names>
<surname>Sanches</surname>
</string-name>, <string-name>
<given-names>G. A. P.</given-names>
<surname>de Oliveira</surname>
</string-name>, <string-name>
<given-names>O. L.</given-names>
<surname>Franco</surname>
</string-name>, and <string-name>
<given-names>F. D.</given-names>
<surname>Silva</surname>
</string-name>. <year>2024</year>. &#x0201c;<article-title>Peptide PaDBS1R6 Has Potent Antibacterial Activity on Clinical Bacterial Isolates and Integrates an Immunomodulatory Peptide Fragment Within Its Sequence</article-title>.&#x0201d; <source>Biochimica et Biophysica Acta (BBA) &#x02010; General Subjects</source>
<volume>1868</volume>, no. <issue>11</issue>: <elocation-id>130693</elocation-id>.<pub-id pub-id-type="pmid">39147109</pub-id>
</mixed-citation></ref><ref id="cbdd70130-bib-0041"><mixed-citation publication-type="journal" id="cbdd70130-cit-0041">
<string-name>
<surname>Riahifard</surname>, <given-names>N.</given-names>
</string-name>, <string-name>
<given-names>S.</given-names>
<surname>Mozaffari</surname>
</string-name>, <string-name>
<given-names>T.</given-names>
<surname>Aldakhil</surname>
</string-name>, et&#x000a0;al. <year>2018</year>. &#x0201c;<article-title>Design, Synthesis, and Evaluation of Amphiphilic Cyclic and Linear Peptides Composed of Hydrophobic and Positively&#x02010;Charged Amino Acids as Antibacterial Agents</article-title>.&#x0201d; <source>Molecules</source>
<volume>23</volume>: <elocation-id>2722</elocation-id>.<pub-id pub-id-type="pmid">30360400</pub-id>
</mixed-citation></ref><ref id="cbdd70130-bib-1006"><mixed-citation publication-type="journal" id="cbdd70130-cit-1006">
<string-name>
<surname>Ribera</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Ruiz</surname>
</string-name>, <string-name>
<given-names>E.</given-names>
<surname>Jim&#x000e9;nez</surname>
</string-name>, et&#x000a0;al. <year>2019</year>. &#x0201c;<article-title>Comparative Antibiofilm Efficacy of Meropenem Alone and in Combination with Colistin in an In&#x000a0;Vitro Pharmacodynamic Model by Extended&#x02010;Spectrum&#x02010;&#x003b2;&#x02010;Lactamase&#x02010;Producing <italic toggle="yes">Klebsiella pneumoniae</italic>
</article-title>.&#x0201d; <source>Antimicrobial Agents and Chemotherapy</source>
<volume>63</volume>, no. <issue>11</issue>: <fpage>e01230</fpage>&#x02013;<lpage>e01219</lpage>.<pub-id pub-id-type="pmid">31481437</pub-id>
</mixed-citation></ref><ref id="cbdd70130-bib-0042"><mixed-citation publication-type="journal" id="cbdd70130-cit-0042">
<string-name>
<surname>Roque&#x02010;Borda</surname>, <given-names>C. A.</given-names>
</string-name>, <string-name>
<given-names>L. M. D. G.</given-names>
<surname>Primo</surname>
</string-name>, <string-name>
<given-names>K. P.</given-names>
<surname>Medina&#x02010;Alarc&#x000f3;n</surname>
</string-name>, et&#x000a0;al. <year>2025</year>. &#x0201c;<article-title>Antimicrobial Peptides: A Promising Alternative to Conventional Antimicrobials for Combating Polymicrobial Biofilms</article-title>.&#x0201d; <source>Advanced Science</source>
<volume>12</volume>, no. <issue>1</issue>: <elocation-id>2410893</elocation-id>.<pub-id pub-id-type="pmid">39530703</pub-id>
</mixed-citation></ref><ref id="cbdd70130-bib-0043"><mixed-citation publication-type="journal" id="cbdd70130-cit-0043">
<string-name>
<surname>Santosaningsih</surname>, <given-names>D.</given-names>
</string-name>, <string-name>
<given-names>Y.</given-names>
<surname>Mulyastuti</surname>
</string-name>, <string-name>
<given-names>S.</given-names>
<surname>Poejiani</surname>
</string-name>, et&#x000a0;al. <year>2024</year>. &#x0201c;<article-title>The Biofilm Inhibition Properties of Glucosamine Gold Nanoparticles in Combination With Meropenem Against Pseudomonas Aeruginosa on the Endotracheal Tube: A Model of Biofilm&#x02010;Related Ventilator&#x02010;Associated Pneumonia</article-title>.&#x0201d; <source>Materials</source>
<volume>17</volume>, no. <issue>7</issue>: <elocation-id>1604</elocation-id>.<pub-id pub-id-type="pmid">38612117</pub-id>
</mixed-citation></ref><ref id="cbdd70130-bib-0044"><mixed-citation publication-type="journal" id="cbdd70130-cit-0044">
<string-name>
<surname>Silhavy</surname>, <given-names>T. J.</given-names>
</string-name>, <string-name>
<given-names>D.</given-names>
<surname>Kahne</surname>
</string-name>, and <string-name>
<given-names>S.</given-names>
<surname>Walker</surname>
</string-name>. <year>2010</year>. &#x0201c;<article-title>The Bacterial Cell Envelope</article-title>.&#x0201d; <source>Cold Spring Harbor Perspectives in Biology</source>
<volume>2</volume>: <elocation-id>a000414</elocation-id>.<pub-id pub-id-type="pmid">20452953</pub-id>
</mixed-citation></ref><ref id="cbdd70130-bib-0045"><mixed-citation publication-type="journal" id="cbdd70130-cit-0045">
<string-name>
<surname>Silva</surname>, <given-names>P. S. e.</given-names>
</string-name>, <string-name>
<given-names>A. S.</given-names>
<surname>Guindo</surname>
</string-name>, <string-name>
<given-names>P. H. C.</given-names>
<surname>Oliveira</surname>
</string-name>, et&#x000a0;al. <year>2023</year>. &#x0201c;<article-title>Evaluation of the Synthetic Multifunctional Peptide Hp&#x02010;MAP3 Derivative of Temporin&#x02010;PTa</article-title>.&#x0201d; <source>Toxins</source>
<volume>15</volume>, no. <issue>1</issue>: <fpage>42</fpage>.<pub-id pub-id-type="pmid">36668862</pub-id>
</mixed-citation></ref><ref id="cbdd70130-bib-0046"><mixed-citation publication-type="journal" id="cbdd70130-cit-0046">
<string-name>
<surname>Slezina</surname>, <given-names>M. P.</given-names>
</string-name>, <string-name>
<given-names>E. A.</given-names>
<surname>Istomina</surname>
</string-name>, <string-name>
<given-names>E. V.</given-names>
<surname>Kulakovskaya</surname>
</string-name>, <string-name>
<given-names>T. V.</given-names>
<surname>Korostyleva</surname>
</string-name>, and <string-name>
<given-names>T. I.</given-names>
<surname>Odintsova</surname>
</string-name>. <year>2022</year>. &#x0201c;<article-title>The &#x003b3;&#x02010;Core Motif Peptides of AMPs From Grasses Display Inhibitory Activity Against Human and Plant Pathogens</article-title>.&#x0201d; <source>International Journal of Molecular Sciences</source>
<volume>23</volume>: <elocation-id>8383</elocation-id>.<pub-id pub-id-type="pmid">35955519</pub-id>
</mixed-citation></ref><ref id="cbdd70130-bib-1003"><mixed-citation publication-type="journal" id="cbdd70130-cit-1003">
<string-name>
<surname>Souza E Silva</surname>, <given-names>P.</given-names>
</string-name>, <string-name>
<given-names>M. A.</given-names>
<surname>Ferreira</surname>
</string-name>, <string-name>
<given-names>L. F. R.</given-names>
<surname>de Moraes</surname>
</string-name>, et&#x000a0;al. <year>2022</year>. &#x0201c;<article-title>Synthetic Peptides Bioinspired in Temporin&#x02010;PTa with Antibacterial and Antibiofilm Activity</article-title>.&#x0201d; <source>Chemical Biology &#x00026; Drug Design</source>
<volume>100</volume>, no. <issue>1</issue>: <fpage>51</fpage>&#x02013;<lpage>63</lpage>.<pub-id pub-id-type="pmid">35377553</pub-id>
</mixed-citation></ref><ref id="cbdd70130-bib-0047"><mixed-citation publication-type="journal" id="cbdd70130-cit-0047">
<string-name>
<surname>Suchi</surname>, <given-names>S. A.</given-names>
</string-name>, <string-name>
<given-names>D. Y.</given-names>
<surname>Lee</surname>
</string-name>, <string-name>
<given-names>Y. K.</given-names>
<surname>Kim</surname>
</string-name>, <string-name>
<given-names>S. S.</given-names>
<surname>Kang</surname>
</string-name>, <string-name>
<given-names>T.</given-names>
<surname>Bilkis</surname>
</string-name>, and <string-name>
<given-names>J. C.</given-names>
<surname>Yoo</surname>
</string-name>. <year>2023</year>. &#x0201c;<article-title>Synergistic Effect, Improved Cell Selectivity, and Elucidating the Action Mechanism of Antimicrobial Peptide YS12</article-title>.&#x0201d; <source>International Journal of Molecular Sciences</source>
<volume>24</volume>: <elocation-id>13522</elocation-id>.<pub-id pub-id-type="pmid">37686328</pub-id>
</mixed-citation></ref><ref id="cbdd70130-bib-0048"><mixed-citation publication-type="journal" id="cbdd70130-cit-0048">
<string-name>
<surname>Trott</surname>, <given-names>O.</given-names>
</string-name>, and <string-name>
<given-names>A. J.</given-names>
<surname>Olson</surname>
</string-name>. <year>2010</year>. &#x0201c;<article-title>AutoDock Vina: Improving the Speed and Accuracy of Docking With a New Scoring Function, Efficient Optimization, and Multithreading</article-title>.&#x0201d; <source>Journal of Computational Chemistry</source>
<volume>31</volume>: <fpage>455</fpage>&#x02013;<lpage>461</lpage>.<pub-id pub-id-type="pmid">19499576</pub-id>
</mixed-citation></ref><ref id="cbdd70130-bib-0049"><mixed-citation publication-type="journal" id="cbdd70130-cit-0049">
<string-name>
<surname>Uchikoga</surname>, <given-names>N.</given-names>
</string-name>, <string-name>
<given-names>Y.</given-names>
<surname>Matsuzaki</surname>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Ohue</surname>
</string-name>, <string-name>
<given-names>T.</given-names>
<surname>Hirokawa</surname>
</string-name>, and <string-name>
<given-names>Y.</given-names>
<surname>Akiyama</surname>
</string-name>. <year>2013</year>. &#x0201c;<article-title>Re&#x02010;Docking Scheme for Generating Near&#x02010;Native Protein Complexes by Assembling Residue Interaction Fingerprints</article-title>.&#x0201d; <source>PLoS One</source>
<volume>8</volume>: <elocation-id>e69365</elocation-id>.<pub-id pub-id-type="pmid">23874954</pub-id>
</mixed-citation></ref><ref id="cbdd70130-bib-0050"><mixed-citation publication-type="journal" id="cbdd70130-cit-0050">
<string-name>
<surname>Versey</surname>, <given-names>Z.</given-names>
</string-name>, <string-name>
<given-names>W. S.</given-names>
<surname>da Cruz Nizer</surname>
</string-name>, <string-name>
<given-names>E.</given-names>
<surname>Russell</surname>
</string-name>, et&#x000a0;al. <year>2021</year>. &#x0201c;<article-title>Biofilm&#x02010;Innate Immune Interface: Contribution to Chronic Wound Formation</article-title>.&#x0201d; <source>Frontiers in Immunology</source>
<volume>12</volume>, no. <issue>2021</issue>: <elocation-id>648554</elocation-id>.<pub-id pub-id-type="pmid">33897696</pub-id>
</mixed-citation></ref><ref id="cbdd70130-bib-0051"><mixed-citation publication-type="journal" id="cbdd70130-cit-0051">
<string-name>
<surname>Wang</surname>, <given-names>C.</given-names>
</string-name>, <string-name>
<given-names>T.</given-names>
<surname>Hong</surname>
</string-name>, <string-name>
<given-names>P.</given-names>
<surname>Cui</surname>
</string-name>, <string-name>
<given-names>J.</given-names>
<surname>Wang</surname>
</string-name>, and <string-name>
<given-names>J.</given-names>
<surname>Xia</surname>
</string-name>. <year>2021</year>. &#x0201c;<article-title>Antimicrobial Peptides Towards Clinical Application: Delivery and Formulation</article-title>.&#x0201d; <source>Advanced Drug Delivery Reviews</source>
<volume>175</volume>: <elocation-id>113818</elocation-id>.<pub-id pub-id-type="pmid">34090965</pub-id>
</mixed-citation></ref><ref id="cbdd70130-bib-0052"><mixed-citation publication-type="journal" id="cbdd70130-cit-0052">
<string-name>
<surname>White</surname>, <given-names>S. H.</given-names>
</string-name>, and <string-name>
<given-names>W. C.</given-names>
<surname>Wimley</surname>
</string-name>. <year>1999</year>. &#x0201c;<article-title>Membrane Protein Folding and Stability: Physical Principles</article-title>.&#x0201d; <source>Annual Review of Biophysics and Biomolecular Structure</source>
<volume>28</volume>: <fpage>319</fpage>&#x02013;<lpage>365</lpage>.</mixed-citation></ref><ref id="cbdd70130-bib-0053"><mixed-citation publication-type="journal" id="cbdd70130-cit-0053">
<string-name>
<surname>Wiegand</surname>, <given-names>I.</given-names>
</string-name>, <string-name>
<given-names>K.</given-names>
<surname>Hilpert</surname>
</string-name>, and <string-name>
<given-names>R. E. W.</given-names>
<surname>Hancock</surname>
</string-name>. <year>2008</year>. &#x0201c;<article-title>Agar and Broth Dilution Methods to Determine the Minimal Inhibitory Concentration (MIC) of Antimicrobial Substances</article-title>.&#x0201d; <source>Nature Protocols</source>
<volume>3</volume>: <fpage>163</fpage>&#x02013;<lpage>175</lpage>.<pub-id pub-id-type="pmid">18274517</pub-id>
</mixed-citation></ref><ref id="cbdd70130-bib-0054"><mixed-citation publication-type="journal" id="cbdd70130-cit-0054">
<string-name>
<surname>Wu</surname>, <given-names>W. U.</given-names>
</string-name>, <string-name>
<given-names>N. S.</given-names>
<surname>Hettiarachchy</surname>
</string-name>, and <string-name>
<given-names>M.</given-names>
<surname>Qi</surname>
</string-name>. <year>1998</year>. &#x0201c;<article-title>Hydrophobicity, Solubility, and Emulsifying Properties of Soy Protein Peptides Prepared by Papain Modification and Ultrafiltration</article-title>.&#x0201d; <source>Journal of the American Oil Chemists' Society</source>
<volume>75</volume>: <fpage>845</fpage>&#x02013;<lpage>850</lpage>.</mixed-citation></ref><ref id="cbdd70130-bib-0055"><mixed-citation publication-type="journal" id="cbdd70130-cit-0055">
<string-name>
<surname>Xuan</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<given-names>W.</given-names>
<surname>Feng</surname>
</string-name>, <string-name>
<given-names>J.</given-names>
<surname>Wang</surname>
</string-name>, et&#x000a0;al. <year>2023</year>. &#x0201c;<article-title>Antimicrobial Peptides for Combating Drug&#x02010;Resistant Bacterial Infections</article-title>.&#x0201d; <source>Drug Resistance Updates</source>
<volume>68</volume>: <elocation-id>100954</elocation-id>.<pub-id pub-id-type="pmid">36905712</pub-id>
</mixed-citation></ref><ref id="cbdd70130-bib-0056"><mixed-citation publication-type="journal" id="cbdd70130-cit-0056">
<string-name>
<surname>Yang</surname>, <given-names>Y.</given-names>
</string-name>, <string-name>
<given-names>Z.</given-names>
<surname>Yu</surname>
</string-name>, <string-name>
<given-names>Z.</given-names>
<surname>Ba</surname>
</string-name>, et&#x000a0;al. <year>2024</year>. &#x0201c;<article-title>Arginine and Tryptophan&#x02010;Rich Dendritic Antimicrobial Peptides That Disrupt Membranes for Bacterial Infection In&#x000a0;Vivo</article-title>.&#x0201d; <source>European Journal of Medicinal Chemistry</source>
<volume>271</volume>: <elocation-id>116451</elocation-id>.<pub-id pub-id-type="pmid">38691892</pub-id>
</mixed-citation></ref><ref id="cbdd70130-bib-0057"><mixed-citation publication-type="journal" id="cbdd70130-cit-0057">
<string-name>
<surname>Yazawa</surname>, <given-names>K.</given-names>
</string-name>, and <string-name>
<given-names>K.</given-names>
<surname>Numata</surname>
</string-name>. <year>2016</year>. &#x0201c;<article-title>Papain&#x02010;Catalyzed Synthesis of Polyglutamate Containing a Nylon Monomer Unit</article-title>.&#x0201d; <source>Polymers (Basel)</source>
<volume>8</volume>: <elocation-id>194</elocation-id>.<pub-id pub-id-type="pmid">30979286</pub-id>
</mixed-citation></ref><ref id="cbdd70130-bib-0058"><mixed-citation publication-type="journal" id="cbdd70130-cit-0058">
<string-name>
<surname>Yeaman</surname>, <given-names>M. R.</given-names>
</string-name>, and <string-name>
<given-names>N. Y.</given-names>
<surname>Yount</surname>
</string-name>. <year>2003</year>. &#x0201c;<article-title>Mechanisms of Antimicrobial Peptide Action and Resistance</article-title>.&#x0201d; <source>Pharmacological Reviews</source>
<volume>55</volume>: <fpage>27</fpage>&#x02013;<lpage>55</lpage>.<pub-id pub-id-type="pmid">12615953</pub-id>
</mixed-citation></ref><ref id="cbdd70130-bib-0059"><mixed-citation publication-type="journal" id="cbdd70130-cit-0059">
<string-name>
<surname>Zhang</surname>, <given-names>Y.&#x02010;M.</given-names>
</string-name>, and <string-name>
<given-names>C. O.</given-names>
<surname>Rock</surname>
</string-name>. <year>2008</year>. &#x0201c;<article-title>Membrane Lipid Homeostasis in Bacteria</article-title>.&#x0201d; <source>Nature Reviews. Microbiology</source>
<volume>6</volume>: <fpage>222</fpage>&#x02013;<lpage>233</lpage>.<pub-id pub-id-type="pmid">18264115</pub-id>
</mixed-citation></ref></ref-list></back></article>